cached image

David M. Holtzman - Publications

Affiliations: 
Neurology Washington University, Saint Louis, St. Louis, MO 
Area:
Alzheimer's, amyloid
Website:
http://neuro.wustl.edu/aboutus/facultybiographies/holtzman.htm

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Hu Y, Kirmess KM, Meyer MR, Rabinovici GD, Gatsonis C, Siegel BA, Whitmer RA, Apgar C, Hanna L, Kanekiyo M, Kaplow J, Koyama A, Verbel D, Holubasch MS, Knapik SS, ... ... Holtzman DM, et al. Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. Jama Network Open. 5: e228392. PMID 35446396 DOI: 10.1001/jamanetworkopen.2022.8392  0.331
2022 Budelier MM, He Y, Barthelemy NR, Jiang H, Li Y, Park E, Henson RL, Schindler SE, Holtzman DM, Bateman RJ. A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer's disease. Brain Communications. 4: fcac045. PMID 35415607 DOI: 10.1093/braincomms/fcac045  0.521
2022 Strain JF, Barthelemy N, Horie K, Gordon BA, Kilgore C, Aschenbrenner A, Cruchaga C, Xiong C, Joseph-Mathurin N, Hassenstab J, Fagan AM, Li Y, Karch CM, Perrin RJ, Berman SB, ... ... Holtzman DM, et al. CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease. 168: 105714. PMID 35358703 DOI: 10.1016/j.nbd.2022.105714  0.566
2022 Martens YA, Zhao N, Liu CC, Kanekiyo T, Yang AJ, Goate AM, Holtzman DM, Bu G. ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias. Neuron. PMID 35298921 DOI: 10.1016/j.neuron.2022.03.004  0.327
2022 Gratuze M, Jiang H, Wang C, Xiong M, Bao X, Holtzman DM. APOE Antibody Inhibits Aβ-Associated Tau Seeding and Spreading in a Mouse Model. Annals of Neurology. PMID 35285073 DOI: 10.1002/ana.26351  0.445
2022 Parhizkar S, Holtzman DM. APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease. Seminars in Immunology. 101594. PMID 35232622 DOI: 10.1016/j.smim.2022.101594  0.406
2022 Mann CN, Devi SS, Kersting CT, Bleem AV, Karch CM, Holtzman DM, Gallardo G. Astrocytic α2-Na/K ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model. Science Translational Medicine. 14: eabm4107. PMID 35171651 DOI: 10.1126/scitranslmed.abm4107  0.361
2022 Mahan TE, Wang C, Bao X, Choudhury A, Ulrich JD, Holtzman DM. Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis. Molecular Neurodegeneration. 17: 13. PMID 35109920 DOI: 10.1186/s13024-022-00516-0  0.451
2022 Bigley TM, Xiong M, Ali M, Chen Y, Wang C, Serrano JR, Eteleeb A, Harari O, Yang L, Patel SJ, Cruchaga C, Yokoyama WM, Holtzman DM. Murine roseolovirus does not accelerate amyloid-β pathology and human roseoloviruses are not over-represented in Alzheimer disease brains. Molecular Neurodegeneration. 17: 10. PMID 35033173 DOI: 10.1186/s13024-021-00514-8  0.383
2021 Mehla J, Singh I, Diwan D, Nelson JW, Lawrence M, Lee E, Bauer AQ, Holtzman DM, Zipfel GJ. STAT3 inhibitor mitigates cerebral amyloid angiopathy and parenchymal amyloid plaques while improving cognitive functions and brain networks. Acta Neuropathologica Communications. 9: 193. PMID 34911575 DOI: 10.1186/s40478-021-01293-5  0.372
2021 Musiek ES, Gomez-Isla T, Holtzman DM. Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside. The Journal of Clinical Investigation. 131. PMID 34651585 DOI: 10.1172/JCI154889  0.386
2021 Schindler S, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, Coble D, Klunk WE, Fagan AM, Holtzman D, Bateman RJ, Morris JC, Xiong C. Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology. PMID 34504028 DOI: 10.1212/WNL.0000000000012775  0.562
2021 Wang H, Kulas JA, Wang C, Holtzman DM, Ferris HA, Hansen SB. Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34385305 DOI: 10.1073/pnas.2102191118  0.34
2021 Chen X, Sun G, Tian E, Zhang M, Davtyan H, Beach TG, Reiman EM, Blurton-Jones M, Holtzman DM, Shi Y. Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). e2101462. PMID 34337898 DOI: 10.1002/advs.202101462  0.4
2021 McDade E, Llibre-Guerra JJ, Holtzman DM, Morris JC, Bateman RJ. The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration. 16: 49. PMID 34289882 DOI: 10.1186/s13024-021-00467-y  0.57
2021 Shi Y, Andhey PS, Ising C, Wang K, Snipes LL, Boyer K, Lawson S, Yamada K, Qin W, Manis M, Serrano JR, Benitez BA, Schmidt RE, Artyomov M, Ulrich JD, ... Holtzman DM, et al. Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms. Neuron. PMID 34157306 DOI: 10.1016/j.neuron.2021.05.034  0.335
2021 Gratuze M, Chen Y, Parhizkar S, Jain N, Strickland MR, Serrano JR, Colonna M, Ulrich JD, Holtzman DM. Activated microglia mitigate Aβ-associated tau seeding and spreading. The Journal of Experimental Medicine. 218. PMID 34100905 DOI: 10.1084/jem.20210542  0.425
2021 Butt OH, Meeker KL, Wisch JK, Schindler SE, Fagan AM, Benzinger TLS, Cruchaga C, Holtzman DM, Morris JC, Ances BM. Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 34002449 DOI: 10.1002/alz.12375  0.389
2021 Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, Nixon RA, Jones DT. Alzheimer disease. Nature Reviews. Disease Primers. 7: 33. PMID 33986301 DOI: 10.1038/s41572-021-00269-y  0.388
2021 West T, Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Contois JH, Jackson EN, Harpstrite SE, Bateman RJ, Holtzman DM, Verghese PB, Fogelman I, Braunstein JB, Yarasheski KE. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Molecular Neurodegeneration. 16: 30. PMID 33933117 DOI: 10.1186/s13024-021-00451-6  0.831
2021 Da Mesquita S, Papadopoulos Z, Dykstra T, Brase L, Farias FG, Wall M, Jiang H, Kodira CD, de Lima KA, Herz J, Louveau A, Goldman DH, Salvador AF, Onengut-Gumuscu S, Farber E, ... ... Holtzman DM, et al. Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy. Nature. PMID 33911285 DOI: 10.1038/s41586-021-03489-0  0.699
2021 Spears LD, Adak S, Dong G, Wei X, Spyropoulos G, Zhang Q, Yin L, Feng C, Hu D, Lodhi IJ, Hsu FF, Rajagopal R, Noguchi KK, Halabi CM, Brier L, ... ... Holtzman DM, et al. Endothelial ether lipids link the vasculature to blood pressure, behavior, and neurodegeneration. Journal of Lipid Research. 100079. PMID 33894211 DOI: 10.1016/j.jlr.2021.100079  0.507
2021 Wang C, Xiong M, Gratuze M, Bao X, Shi Y, Andhey PS, Manis M, Schroeder C, Yin Z, Madore C, Butovsky O, Artyomov M, Ulrich JD, Holtzman DM. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron. PMID 33831349 DOI: 10.1016/j.neuron.2021.03.024  0.349
2021 Butt OH, Long JM, Henson RL, Herries E, Sutphen CL, Fagan AM, Cruchaga C, Ladenson JH, Holtzman DM, Morris JC, Ances BM, Schindler SE. Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25. Neurobiology of Aging. 102: 64-72. PMID 33765432 DOI: 10.1016/j.neurobiolaging.2021.02.008  0.355
2021 Xiong M, Jiang H, Serrano JR, Gonzales ER, Wang C, Gratuze M, Hoyle R, Bien-Ly N, Silverman AP, Sullivan PM, Watts RJ, Ulrich JD, Zipfel GJ, Holtzman DM. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Science Translational Medicine. 13. PMID 33597265 DOI: 10.1126/scitranslmed.abd7522  0.407
2021 Litvinchuk A, Huynh TV, Shi Y, Jackson RJ, Finn MB, Manis M, Francis CM, Tran A, Sullivan PM, Ulrich JD, Hyman BT, Cole T, Holtzman DM. ApoE4 reduction with ASOs decreases neurodegeneration in a tauopathy model. Annals of Neurology. PMID 33550655 DOI: 10.1002/ana.26043  0.354
2021 Smith R, Strain J, Tanenbaum A, Fagan A, Hassenstab J, Mcdade E, Schindler S, Gordon B, Xiong C, Chhatwal J, Jack CR, Karch C, Berman S, Brosch J, Lah J, ... ... Holtzman D, et al. Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity. PMID 33430685 DOI: 10.1089/brain.2020.0808  0.524
2020 Krishnan N, Chen X, Donnelly-Roberts D, Mohler EG, Holtzman DM, Gopalakrishnan SM. Small Molecule Phenotypic Screen Identifies Novel Regulators of LDLR Expression. Acs Chemical Biology. PMID 33270420 DOI: 10.1021/acschembio.0c00851  0.315
2020 Chen Y, Strickland MR, Soranno A, Holtzman DM. Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis. Neuron. PMID 33176118 DOI: 10.1016/j.neuron.2020.10.008  0.358
2020 Carare RO, Aldea R, Agarwal N, Bacskai BJ, Bechman I, Boche D, Bu G, Bulters D, Clemens A, Counts SE, de Leon M, Eide PK, Fossati S, Greenberg SM, Hamel E, ... ... Holtzman D, et al. Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA): Cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer's disease-Opportunities for Therapy. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12053. PMID 32775596 DOI: 10.1002/Dad2.12053  0.466
2020 Wong MY, Lewis M, Doherty JJ, Shi Y, Cashikar AG, Amelianchik A, Tymchuk S, Sullivan PM, Qian M, Covey DF, Petsko GA, Holtzman DM, Paul SM, Luo W. 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner. Journal of Neuroinflammation. 17: 192. PMID 32552741 DOI: 10.1186/S12974-020-01869-3  0.35
2020 Gratuze M, Leyns CE, Sauerbeck AD, St-Pierre MK, Xiong M, Kim N, Remolina Serrano J, Tremblay MÈ, Kummer TT, Colonna M, Ulrich JD, Holtzman DM. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. The Journal of Clinical Investigation. PMID 32544086 DOI: 10.1172/Jci138179  0.844
2020 Cable J, Holtzman DM, Hyman BT, Tansey MG, Colonna M, Kellis M, Brinton RD, Albert M, Wellington CL, Sisodia SS, Tanzi RE. Alternatives to amyloid for Alzheimer's disease therapies-a symposium report. Annals of the New York Academy of Sciences. PMID 32472577 DOI: 10.1111/Nyas.14371  0.314
2020 Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, Cella M, Ulland TK, Zaitsev K, Miyashita A, Ikeuchi T, ... ... Holtzman DM, et al. Author Correction: Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nature Medicine. PMID 32409732 DOI: 10.1038/S41591-020-0922-4  0.714
2020 Xu Y, Du S, Marsh JA, Horie K, Sato C, Ballabio A, Karch CM, Holtzman DM, Zheng H. TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading. Molecular Psychiatry. PMID 32366951 DOI: 10.1038/S41380-020-0738-0  0.593
2020 Davis AA, Inman CE, Wargel ZM, Dube U, Freeberg BM, Galluppi A, Haines JN, Dhavale DD, Miller R, Choudhury FA, Sullivan PM, Cruchaga C, Perlmutter JS, Ulrich JD, Benitez BA, ... ... Holtzman DM, et al. genotype regulates pathology and disease progression in synucleinopathy. Science Translational Medicine. 12. PMID 32024799 DOI: 10.1126/Scitranslmed.Aay3069  0.312
2020 Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, Cella M, Ulland TK, Zaitsev K, Miyashita A, Ikeuchi T, ... ... Holtzman DM, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nature Medicine. 26: 131-142. PMID 31932797 DOI: 10.1038/S41591-019-0695-9  0.767
2020 Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L, Xiong C, Morris JC, Benzinger TLS, Holtzman DM. Erratum: Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease (Science Translational Medicine DOI: 10.1126/scitranslmed.aau6550) Science Translational Medicine. 12. PMID 31915302 DOI: 10.1126/Scitranslmed.Aba5187  0.35
2019 Gallardo G, Holtzman DM. Amyloid-β and Tau at the Crossroads of Alzheimer's Disease. Advances in Experimental Medicine and Biology. 1184: 187-203. PMID 32096039 DOI: 10.1007/978-981-32-9358-8_16  0.395
2019 Jack CR, Holtzman DM, Sperling R. Dementia is not synonymous with Alzheimer's disease. Science Translational Medicine. 11. PMID 31826979 DOI: 10.1126/Scitranslmed.Aav0511  0.307
2019 Llibre-Guerra JJ, Li Y, Schindler SE, Gordon BA, Fagan AM, Morris JC, Benzinger TLS, Hassenstab J, Wang G, Allegri R, Berman SB, Chhatwal J, Farlow MR, Holtzman DM, Jucker M, et al. Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. Jama Network Open. 2: e1917126. PMID 31825500 DOI: 10.1001/jamanetworkopen.2019.17126  0.574
2019 Seo DO, Holtzman DM. Gut microbiota: from the forgotten organ to a potential key player in the pathology of Alzheimer disease. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. PMID 31738402 DOI: 10.1093/gerona/glz262  0.334
2019 Huynh TV, Wang C, Tran AC, Tabor GT, Mahan TE, Francis CM, Finn MB, Spellman R, Manis M, Tanzi RE, Ulrich JD, Holtzman DM. Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model. Molecular Neurodegeneration. 14: 37. PMID 31623648 DOI: 10.1186/S13024-019-0337-1  0.451
2019 Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, Hoyle R, Holtzman DM. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. The Journal of Experimental Medicine. PMID 31601677 DOI: 10.1084/Jem.20190980  0.375
2019 Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 179: 312-339. PMID 31564456 DOI: 10.1016/J.Cell.2019.09.001  0.348
2019 Xu J, Sun J, Perrin RJ, Mach RH, Bales KR, Morris JC, Benzinger TLS, Holtzman DM. Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains. Annals of Clinical and Translational Neurology. 6: 1423-1434. PMID 31402620 DOI: 10.1002/Acn3.50837  0.693
2019 Del-Aguila JL, Li Z, Dube U, Mihindukulasuriya KA, Budde JP, Fernandez MV, Ibanez L, Bradley J, Wang F, Bergmann K, Davenport R, Morris JC, Holtzman DM, Perrin RJ, Benitez BA, et al. A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimer's Research & Therapy. 11: 71. PMID 31399126 DOI: 10.1186/S13195-019-0524-X  0.689
2019 Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. PMID 31371569 DOI: 10.1212/Wnl.0000000000008081  0.618
2019 Leyns CEG, Gratuze M, Narasimhan S, Jain N, Koscal LJ, Jiang H, Manis M, Colonna M, Lee VMY, Ulrich JD, Holtzman DM. TREM2 function impedes tau seeding in neuritic plaques. Nature Neuroscience. PMID 31235932 DOI: 10.1038/S41593-019-0433-0  0.479
2019 Wiseman FK, Pulford LJ, Barkus C, Liao F, Portelius E, Webb R, Chavez-Gutierrez L, Cleverley K, Noy S, Sheppard O, Collins T, Powell C, Sarell CJ, Rickman M, Choong X, ... ... Holtzman DM, et al. Trisomy of human chromosome 21 enhances amyloid-beta 3 deposition independently of an extra copy of APP (vol 141, pg 2457, 2018) Brain. 142. PMID 30879033 DOI: 10.1093/Brain/Awz061  0.333
2019 Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, Wang G, Graham DL, Shaw LM, Trojanowski JQ, Hassenstab JJ, Benzinger TLS, Cruchaga C, Jucker M, Levin J, ... ... Holtzman DM, et al. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30846386 DOI: 10.1016/J.Jalz.2018.12.019  0.612
2019 Patel TK, Habimana-Griffin L, Gao X, Xu B, Achilefu S, Alitalo K, McKee CA, Sheehan PW, Musiek ES, Xiong C, Coble D, Holtzman DM. Dural lymphatics regulate clearance of extracellular tau from the CNS. Molecular Neurodegeneration. 14: 11. PMID 30813965 DOI: 10.1186/S13024-019-0312-X  0.487
2019 Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, Li Y, Hassenstab J, Aschenbrenner A, Hornbeck R, Jack CR, ... ... Holtzman DM, et al. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. Brain : a Journal of Neurology. PMID 30753379 DOI: 10.1093/Brain/Awz019  0.621
2019 Strickland MR, Holtzman DM. Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1. The Journal of Clinical Investigation. PMID 30741722 DOI: 10.1172/JCI127578  0.399
2019 Ju YS, Holtzman DM. Reply to "Obstructive sleep apnea treatment and amyloid-β in cerebrospinal fluid". Annals of Neurology. PMID 30706528 DOI: 10.1002/Ana.25424  0.553
2019 Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, Finn MB, Manis M, Geerling JC, Fuller PM, Lucey BP, Holtzman DM. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science (New York, N.Y.). PMID 30679382 DOI: 10.1126/Science.Aav2546  0.674
2019 Jagust W, Jack CR, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, et al. "Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia". Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 15: 153-157. PMID 30642435 DOI: 10.1016/J.Jalz.2018.11.002  0.411
2019 Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L, Xiong C, Morris JC, Benzinger TLS, Holtzman DM. Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease. Science Translational Medicine. 11. PMID 30626715 DOI: 10.1126/Scitranslmed.Aau6550  0.362
2019 Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, Müller SA, Colombo A, Monasor LS, ... ... Holtzman DM, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nature Neuroscience. PMID 30617257 DOI: 10.1038/S41593-018-0296-9  0.378
2019 Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, Fagan AM, Grant E, Gordon BA, Holtzman DM, Xiong C. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. Jama Neurology. PMID 30615028 DOI: 10.1001/Jamaneurol.2018.4249  0.399
2019 Li Y, Schindler SE, Llibre Guerra JJ, Bollinger JG, Ovod V, Mawuenyega KG, Gordon BA, Holtzman DM, Morris JC, Benzinger TL, Xiong C, Fagan AM, Bateman R. PLASMA Aβ42/Aβ40 PREDICTS HIPPOCAMPAL ATROPHY Alzheimer's & Dementia. 15: P191-P192. DOI: 10.1016/J.Jalz.2019.06.4519  0.581
2019 Florian H, Arnold SE, Bateman R, Braunstein JB, Budur K, Kerwin DR, Soares H, Wang D, Holtzman DM. ABBV-8E12, A HUMANIZED ANTI-TAU MONOCLONAL ANTIBODY, FOR TREATING EARLY ALZHEIMER’S DISEASE: UPDATED DESIGN AND BASELINE CHARACTERISTICS OF A PHASE 2 STUDY Alzheimer's & Dementia. 15: P251-P252. DOI: 10.1016/J.Jalz.2019.06.075  0.527
2018 Ju YS, Zangrilli MA, Finn MB, Fagan AM, Holtzman DM. Obstructive sleep apnea treatment, slow wave activity, and amyloid-β. Annals of Neurology. PMID 30597615 DOI: 10.1002/Ana.25408  0.632
2018 Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in Alzheimer's disease. Molecular Neurodegeneration. 13: 66. PMID 30572908 DOI: 10.1186/S13024-018-0298-9  0.506
2018 Huynh TV, Holtzman DM. Amyloid-β 'seeds' in old vials of growth hormone. Nature. 564: 354-355. PMID 30546137 DOI: 10.1038/D41586-018-07604-6  0.385
2018 Babulal GM, Chen S, Williams MM, Trani JF, Bakhshi P, Chao GL, Stout SH, Fagan AM, Benzinger TLS, Holtzman DM, Morris JC, Roe CM. Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. Journal of Alzheimer's Disease : Jad. PMID 30400098 DOI: 10.3233/Jad-180564  0.38
2018 Lessard CB, Malnik SL, Zhou Y, Ladd TB, Cruz PE, Ran Y, Mahan TE, Chakrabaty P, Holtzman DM, Ulrich JD, Colonna M, Golde TE. High-affinity interactions and signal transduction between Aβ oligomers and TREM2. Embo Molecular Medicine. PMID 30341064 DOI: 10.15252/Emmm.201809027  0.61
2018 Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV. Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Molecular Neurodegeneration. 13: 57. PMID 30340601 DOI: 10.1186/S13024-018-0286-0  0.789
2018 Roe CM, Ances BM, Head D, Babulal GM, Stout SH, Grant EA, Hassenstab J, Xiong C, Holtzman DM, Benzinger TLS, Schindler SE, Fagan AM, Morris JC. Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain : a Journal of Neurology. PMID 30304397 DOI: 10.1093/Brain/Awy244  0.32
2018 McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. PMID 30217935 DOI: 10.1212/Wnl.0000000000006277  0.55
2018 Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nature Reviews. Immunology. PMID 30140051 DOI: 10.1038/S41577-018-0051-1  0.422
2018 Huynh TV, Holtzman DM. In Search of an Identity for Amyloid Plaques. Trends in Neurosciences. 41: 483-486. PMID 30053949 DOI: 10.1016/J.Tins.2018.06.002  0.447
2018 Davis AA, Leyns CEG, Holtzman DM. Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. Annual Review of Cell and Developmental Biology. PMID 30044648 DOI: 10.1146/Annurev-Cellbio-100617-062636  0.343
2018 Wiseman FK, Pulford LJ, Barkus C, Liao F, Portelius E, Webb R, Chávez-Gutiérrez L, Cleverley K, Noy S, Sheppard O, Collins T, Powell C, Sarell CJ, Rickman M, Choong X, ... ... Holtzman DM, et al. Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP. Brain : a Journal of Neurology. PMID 29945247 DOI: 10.1093/Brain/Awy159  0.423
2018 Roe CM, Babulal GM, Stout SH, Ott BR, Carr DB, Williams MM, Benzinger TLS, Fagan AM, Holtzman DM, Ances BM, Morris JC. Using the A/T/N Framework to Examine Driving in Preclinical AD. Geriatrics (Basel, Switzerland). 3. PMID 29805967 DOI: 10.3390/Geriatrics3020023  0.428
2018 Hettinger JC, Lee H, Bu G, Holtzman DM, Cirrito JR. AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model. Molecular Neurodegeneration. 13: 22. PMID 29764453 DOI: 10.1186/S13024-018-0256-6  0.709
2018 Lee S, Zimmerman ME, Narkhede A, Nasrabady SE, Tosto G, Meier IB, Benzinger TLS, Marcus DS, Fagan AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, et al. White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. Plos One. 13: e0195838. PMID 29742105 DOI: 10.1371/Journal.Pone.0195838  0.621
2018 Patel TK, Holtzman DM. Dual therapy for Aβ amyloidosis in AD: A successful one-two combo. The Journal of Experimental Medicine. PMID 29685951 DOI: 10.1084/Jem.20180494  0.444
2018 Mishra S, Blazey TM, Holtzman DM, Cruchaga C, Su Y, Morris JC, Benzinger TLS, Gordon BA. Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ɛ4 genotype. Brain : a Journal of Neurology. PMID 29672664 DOI: 10.1093/Brain/Awy103  0.442
2018 Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 14: 535-562. PMID 29653606 DOI: 10.1016/J.Jalz.2018.02.018  0.441
2018 Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, Finn MB, Hoyle R, Keyser J, Lefton KB, Robinson GO, Serrano JR, Silverman AP, Guo JL, Getz J, ... ... Holtzman DM, et al. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. The Journal of Clinical Investigation. PMID 29600961 DOI: 10.1172/Jci96429  0.838
2018 Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, Fagan AM. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29580670 DOI: 10.1016/J.Jalz.2018.01.012  0.38
2018 Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, Wahl S, Benzinger TLS, Holtzman DM, Morris JC, Fagan AM. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29501462 DOI: 10.1016/J.Jalz.2018.01.013  0.448
2018 Ulrich JD, Ulland TK, Mahan TE, Nyström S, Nilsson KP, Song WM, Zhou Y, Reinartz M, Choi S, Jiang H, Stewart FR, Anderson E, Wang Y, Colonna M, Holtzman DM. ApoE facilitates the microglial response to amyloid plaque pathology. The Journal of Experimental Medicine. PMID 29483128 DOI: 10.1084/Jem.20171265  0.8
2018 Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR, ... ... Holtzman DM, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. The Lancet. Neurology. PMID 29397305 DOI: 10.1016/S1474-4422(18)30028-0  0.624
2018 Kress GJ, Liao F, Dimitry J, Cedeno MR, FitzGerald GA, Holtzman DM, Musiek ES. Regulation of amyloid-β dynamics and pathology by the circadian clock. The Journal of Experimental Medicine. PMID 29382695 DOI: 10.1084/Jem.20172347  0.474
2018 Musiek ES, Bhimasani M, Zangrilli MA, Morris JC, Holtzman DM, Ju YS. Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. Jama Neurology. PMID 29379963 DOI: 10.1001/Jamaneurol.2017.4719  0.625
2018 Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, Craft S, Gandy S, Buettner C, Stoeckel LE, Holtzman DM, Nathan DM. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nature Reviews. Neurology. PMID 29377010 DOI: 10.1038/Nrneurol.2017.185  0.308
2018 Stout SH, Babulal GM, Ma C, Carr DB, Head DM, Grant EA, Williams MM, Holtzman DM, Fagan AM, Morris JC, Roe CM. Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29328928 DOI: 10.1016/J.Jalz.2017.11.011  0.388
2017 Huynh TV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, Roh J, Finn MB, Sullivan PM, Esparza TJ, Stewart FR, Mahan TE, Ulrich JD, Cole T, Holtzman DM. Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis. Neuron. 96: 1013-1023.e4. PMID 29216448 DOI: 10.1016/J.Neuron.2017.11.014  0.523
2017 West T, Hu Y, Verghese PB, Bateman RJ, Braunstein JB, Fogelman I, Budur K, Florian H, Mendonca N, Holtzman DM. Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies. The Journal of Prevention of Alzheimer's Disease. 4: 236-241. PMID 29181488 DOI: 10.14283/jpad.2017.36  0.777
2017 Andrew RJ, Fernandez CG, Stanley M, Jiang H, Nguyen P, Rice RC, Buggia-Prévot V, De Rossi P, Vetrivel KS, Lamb R, Argemi A, Allaert ES, Rathbun EM, Krause SV, Wagner SL, ... ... Holtzman DM, et al. Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 29078331 DOI: 10.1073/Pnas.1708568114  0.418
2017 Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, Holtzman DM. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proceedings of the National Academy of Sciences of the United States of America. 114: 11524-11529. PMID 29073081 DOI: 10.1073/Pnas.1710311114  0.463
2017 Kang SS, Kurti A, Baker KE, Liu CC, Colonna M, Ulrich JD, Holtzman DM, Bu G, Fryer JD. Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal. Human Molecular Genetics. PMID 29040522 DOI: 10.1093/Hmg/Ddx366  0.382
2017 Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, ... ... Holtzman DM, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 549: 523-527. PMID 28959956 DOI: 10.1038/Nature24016  0.351
2017 Cruchaga C, Del-Aguila JL, Saef B, Black K, Fernandez MV, Budde J, Ibanez L, Kapoor M, Tosto G, Mayeux RP, Holtzman DM, Fagan AM, Morris JC, Bateman RJ, Goate AM, et al. Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28943286 DOI: 10.1016/J.Jalz.2017.08.013  0.605
2017 Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, ... ... Holtzman DM, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity. 47: 566-581.e9. PMID 28930663 DOI: 10.1016/J.Immuni.2017.08.008  0.491
2017 Ju YS, Ooms SJ, Sutphen C, Macauley SL, Zangrilli MA, Jerome G, Fagan AM, Mignot E, Zempel JM, Claassen JAHR, Holtzman DM. Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels. Brain : a Journal of Neurology. 140: 2104-2111. PMID 28899014 DOI: 10.1093/Brain/Awx148  0.541
2017 Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, Loginicheva E, Gilfillan S, Cella M, Virgin HW, Unanue ER, ... ... Holtzman DM, et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell. 170: 649-663.e13. PMID 28802038 DOI: 10.1016/J.Cell.2017.07.023  0.771
2017 Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson BW, Bateman RJ. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28734653 DOI: 10.1016/J.Jalz.2017.06.2266  0.595
2017 Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, Mulder SD, Scheltens P, Xiong C, Fagan AM. Upward drift in cerebrospinal fluid amyloid-β 42 assay values for more than 10 years. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28710906 DOI: 10.1016/J.Jalz.2017.06.2264  0.459
2017 Leyns CEG, Holtzman DM. Glial contributions to neurodegeneration in tauopathies. Molecular Neurodegeneration. 12: 50. PMID 28662669 DOI: 10.1186/S13024-017-0192-X  0.501
2017 Ising C, Gallardo G, Leyns CEG, Wong CH, Jiang H, Stewart F, Koscal LJ, Roh J, Robinson GO, Serrano JR, Holtzman DM. Correction: AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. The Journal of Experimental Medicine. PMID 28536241 DOI: 10.1084/Jem.2016212505192017C  0.373
2017 Lucey BP, Fagan AM, Holtzman DM, Morris JC, Bateman RJ. Diurnal oscillation of CSF Aβ and other AD biomarkers. Molecular Neurodegeneration. 12: 36. PMID 28478762 DOI: 10.1186/S13024-017-0161-4  0.614
2017 Babulal GM, Stout SH, Head D, Holtzman DM, Fagan AM, Morris JC, Roe CM. Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report. Journal of Alzheimer's Disease : Jad. PMID 28453487 DOI: 10.3233/Jad-170067  0.427
2017 Roe CM, Babulal GM, Head DM, Stout SH, Vernon EK, Ghoshal N, Garland B, Barco PP, Williams MM, Johnson A, Fierberg R, Fague MS, Xiong C, Mormino E, Grant EA, ... Holtzman DM, et al. Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimer's & Dementia (New York, N. Y.). 3: 74-82. PMID 28435853 DOI: 10.1016/J.Trci.2016.11.006  0.403
2017 Ulrich JD, Ulland TK, Colonna M, Holtzman DM. Elucidating the Role of TREM2 in Alzheimer's Disease. Neuron. 94: 237-248. PMID 28426958 DOI: 10.1016/J.Neuron.2017.02.042  0.78
2017 Yanamandra K, Patel TK, Jiang H, Schindler S, Ulrich JD, Boxer AL, Miller BL, Kerwin DR, Gallardo G, Stewart F, Finn MB, Cairns NJ, Verghese PB, Fogelman I, West T, ... ... Holtzman DM, et al. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Science Translational Medicine. 9. PMID 28424326 DOI: 10.1126/Scitranslmed.Aal2029  0.796
2017 Ising C, Gallardo G, Leyns CEG, Wong CH, Stewart F, Koscal LJ, Roh J, Robinson GO, Remolina Serrano J, Holtzman DM. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. The Journal of Experimental Medicine. PMID 28416651 DOI: 10.1084/Jem.20162125  0.334
2017 Holth JK, Mahan TE, Robinson GO, Rocha A, Holtzman DM. Altered sleep and EEG power in the P301S Tau transgenic mouse model. Annals of Clinical and Translational Neurology. 4: 180-190. PMID 28275652 DOI: 10.1002/Acn3.390  0.332
2017 Liu CC, Hu J, Zhao N, Wang J, Na W, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G. Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 28275161 DOI: 10.1523/Jneurosci.3442-16.2017  0.699
2017 Deming Y, Li Z, Kapoor M, Harari O, Del-Aguila JL, Black K, Carrell D, Cai Y, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Huang KL, Bertelsen S, ... ... Holtzman DM, et al. Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. Acta Neuropathologica. PMID 28247064 DOI: 10.1007/s00401-017-1685-y  0.326
2017 Huynh TV, Davis AA, Ulrich JD, Holtzman DM. Apolipoprotein E and Alzheimer Disease: The influence of apoE on amyloid-β and other amyloidogenic proteins. Journal of Lipid Research. PMID 28246336 DOI: 10.1194/Jlr.R075481  0.524
2017 Ooms SJ, Zempel JM, Holtzman DM, Ju YS. Automated selective disruption of slow wave sleep. Journal of Neuroscience Methods. PMID 28238859 DOI: 10.1016/J.Jneumeth.2017.02.008  0.503
2017 Holth J, Patel T, Holtzman DM. Sleep in Alzheimer's Disease - Beyond Amyloid. Neurobiology of Sleep and Circadian Rhythms. 2: 4-14. PMID 28217760 DOI: 10.1016/J.Nbscr.2016.08.002  0.397
2017 Pankiewicz JE, Baquero-Buitrago J, Sanchez S, Lopez-Contreras J, Kim J, Sullivan PM, Holtzman DM, Sadowski MJ. APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice. Molecular Neurodegeneration. 12: 12. PMID 28143566 DOI: 10.1186/S13024-017-0156-1  0.685
2017 Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takano T, Holtzman DM, Nedergaard M, Deane R. Erratum to: Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Molecular Neurodegeneration. 12: 3. PMID 28081701 DOI: 10.1186/s13024-016-0147-7  0.699
2017 Gallardo G, Holtzman DM. Antibody Therapeutics Targeting Aβ and Tau. Cold Spring Harbor Perspectives in Medicine. PMID 28062555 DOI: 10.1101/cshperspect.a024331  0.36
2017 Ovod V, Bollinger JG, Mawuenyega KG, Hicks TJ, Schneider T, Kasten T, Sigurdson W, Sullivan M, Donahue TA, Ramsey K, Paumier KL, Holtzman DM, Morris JC, Benzinger TL, Fagan AM, et al. CONCENTRATIONS AND STABLE ISOTOPE LABEL KINETICS OF HUMAN PLASMA AMYLOID BETA Alzheimer's & Dementia. 13: P1475-P1476. DOI: 10.1016/J.Jalz.2017.08.005  0.526
2017 Holtzman DM. EFFECTS OF SYNAPTIC ACTIVITY ON Aβ AND TAU FROM PRECLINICAL IN VIVO STUDIES: SIMILARITIES, DIFFERENCES, AND IMPLICATIONS Alzheimer's & Dementia. 13: P1215. DOI: 10.1016/J.Jalz.2017.07.387  0.385
2017 McDade E, Wang G, Benzinger TL, Buckles VD, Fagan AM, Gordon BA, Hassenstab J, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier KL, Xiong C, Ricardo A, et al. LONGITUDINAL BIOMARKER CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE FROM THE DIAN STUDY Alzheimer's & Dementia. 13: P879-P880. DOI: 10.1016/J.Jalz.2017.07.265  0.588
2017 Budur K, West T, Braunstein JB, Fogelman I, Bordelon YM, Litvan I, Roberson ED, Hu H, Verghese PB, Bateman RJ, Florian H, Wang D, Ryman D, Gault L, Goss S, ... ... Holtzman DM, et al. [O2-17-01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO-CONTROLLED STUDY OF ABBV-8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER's DISEASE Alzheimer's & Dementia. 13: P599-P600. DOI: 10.1016/J.Jalz.2017.07.241  0.772
2017 Roe CM, Babulal GM, Stout SH, Fagan AM, Benzinger TLS, Holtzman DM, Ott BR, Carr DB, Xiong C, Morris JC. Impact Of Cognitive Reserve And Preclinical Ad On Longitudinal Driving Performance Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.07.147  0.341
2017 Deming Y, Kapoor M, Li Z, Harari O, Black K, Del-Aguila JL, Carrell D, Cai Y, Fernandez MV, Budde JP, Ma S, Saef B, Howells B, Huang K, Bertelsen S, ... ... Holtzman DM, et al. CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE Alzheimer's & Dementia. 13: P218-P219. DOI: 10.1016/J.Jalz.2017.07.096  0.411
2017 Wiseman FK, Pulford LJ, Barkus C, Liao F, Portelius E, Webb R, Chavez-Gutierrez L, Cleverley K, Noy S, Rickman M, Tosh J, Whittaker H, Stewart F, Szaruga M, Nizetic D, ... ... Holtzman DM, et al. TRISOMY 21 CAUSES A DEFICIT IN LYSOSOMAL CATHEPSINS AND ALTERS APP/Aβ PROCESSING, INDEPENDENTLY OF AN EXTRA COPY OF APP Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.791  0.409
2017 Li A, Jiang H, Lefton K, Robinson GO, Sullivan PM, Roh JD, Holtzman DM. [P1-167]: AAV-MEDIATED EXPRESSION OF HUMAN LDLR MARKEDLY REDUCES AMYLOID DEPOSITION IN A MOUSE MODEL OF AMYLOID-β AMYLOIDOSIS Alzheimer's & Dementia. 13: P307-P307. DOI: 10.1016/J.Jalz.2017.06.234  0.4
2017 Vlassenko AG, Gordon BA, Goyal MS, Su Y, Durbin TJ, Couture LE, Holtzman DM, Morris JC, Fagan AM, Benzinger TL, Bateman RJ, Raichle ME. [IC-P-064]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD Alzheimer's & Dementia. 13: P53-P53. DOI: 10.1016/J.Jalz.2017.06.2337  0.611
2017 Gordon BA, Blazey T, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Fagan AM, Marcus DS, Jack CR, ... ... Holtzman DM, et al. [IC-P-054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK Alzheimer's & Dementia. 13: P44-P45. DOI: 10.1016/J.Jalz.2017.06.2327  0.371
2017 Babulal GM, Stout SH, Head DM, Holtzman DM, Fagan AM, Morris JC, Roe CM. [P4-185]: NEUROPSYCHIATRIC SYMPTOMS AND ALZHEIMER DISEASE BIOMARKERS PREDICT DRIVING DECLINE Alzheimer's & Dementia. 13: P1335-P1335. DOI: 10.1016/J.Jalz.2017.06.2052  0.348
2017 Stout SH, Babulal GM, Ma C, Carr DB, Head DM, Grant EA, Williams MM, Holtzman DM, Fagan AM, Morris JC, Roe CM. Driving Cessation Over A 22-Year Period: Dementia Severity And Csf Biomarkers Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.1811  0.312
2016 Ghosal K, Haag M, Verghese PB, West T, Veenstra T, Braunstein JB, Bateman RJ, Holtzman DM, Landreth GE. A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects. Alzheimer's & Dementia (New York, N. Y.). 2: 110-120. PMID 29067298 DOI: 10.1016/J.Trci.2016.06.001  0.806
2016 Ju YS, Holtzman DM. Reply to "Do repetitive Valsalva maneuvers reduce glymphatic clearance?" Annals of Neurology. PMID 28019658 DOI: 10.1002/Ana.24849  0.517
2016 Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takana T, Holtzman DM, Nedergaard M, Deane R. Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Molecular Neurodegeneration. 11: 74. PMID 27931262 DOI: 10.1186/S13024-016-0138-8  0.741
2016 Stanley M, Macauley SL, Caesar EE, Koscal LJ, Moritz W, Robinson GO, Roh J, Keyser J, Jiang H, Holtzman DM. The Effects of Peripheral and Central High Insulin on Brain Insulin Signaling and Amyloid-β in Young and Old APP/PS1 Mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 11704-11715. PMID 27852778 DOI: 10.1523/Jneurosci.2119-16.2016  0.356
2016 Deming Y, Black K, Carrell D, Cai Y, Del-Aguila JL, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Bertelsen S, Huang KL, Sutphen CL, Tarawneh R, Fagan AM, ... Holtzman DM, et al. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. Bmc Neurology. 16: 217. PMID 27832767 DOI: 10.1186/S12883-016-0742-9  0.362
2016 Baker-Nigh AT, Mawuenyega KG, Bollinger JG, Ovod V, Kasten T, Franklin EE, Liao F, Jiang H, Holtzman D, Cairns NJ, Morris JC, Bateman RJ. Human Central Nervous System (CNS) ApoE Isoforms are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared to Plasma. The Journal of Biological Chemistry. PMID 27793990 DOI: 10.1074/Jbc.M116.721779  0.585
2016 Morales DM, Silver SA, Morgan CD, Mercer D, Inder TE, Holtzman DM, Wallendorf MJ, Rao R, McAllister JP, Limbrick DD. Lumbar Cerebrospinal Fluid Biomarkers of Posthemorrhagic Hydrocephalus of Prematurity: Amyloid Precursor Protein, Soluble Amyloid Precursor Protein α, and L1 Cell Adhesion Molecule. Neurosurgery. PMID 27571524 DOI: 10.1227/Neu.0000000000001415  0.352
2016 Chung WS, Verghese PB, Chakraborty C, Joung J, Hyman BT, Ulrich JD, Holtzman DM, Barres BA. Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proceedings of the National Academy of Sciences of the United States of America. PMID 27559087 DOI: 10.1073/Pnas.1609896113  0.766
2016 Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, Benzinger TL. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. Jama Neurology. PMID 27548756 DOI: 10.1001/Jamaneurol.2016.2642  0.474
2016 Musiek ES, Xiong DD, Patel T, Sasaki Y, Wang Y, Bauer AQ, Singh R, Finn SL, Culver JP, Milbrandt J, Holtzman DM. Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathy. Annals of Clinical and Translational Neurology. 3: 434-42. PMID 27547771 DOI: 10.1002/Acn3.308  0.366
2016 Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, Maruff P, Snyder PJ, Masters CL, Allegri R, Chhatwal J, Farlow MR, Graff-Radford NR, Laske C, Levin J, ... ... Holtzman DM, et al. BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain : a Journal of Neurology. PMID 27521573 DOI: 10.1093/Brain/Aww200  0.584
2016 Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, Musch MW, Liao F, Ward JF, Holtzman DM, Chang EB, Tanzi RE, Sisodia SS. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. Scientific Reports. 6: 30028. PMID 27443609 DOI: 10.1038/Srep30028  0.461
2016 Stanley M, Macauley SL, Holtzman DM. Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence? The Journal of Experimental Medicine. PMID 27432942 DOI: 10.1084/Jem.20160493  0.411
2016 Babulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TL, Fagan AM, Morris JC, Roe CM. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 27426238 DOI: 10.1016/J.Jagp.2016.04.004  0.454
2016 Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, Holtzman DM, Benzinger TL, Morris JC, Fagan AM. Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease. Annals of Neurology. PMID 27398953 DOI: 10.1002/Ana.24719  0.478
2016 Zhao L, Gottesdiener AJ, Parmar M, Li M, Kaminsky SM, Chiuchiolo MJ, Sondhi D, Sullivan PM, Holtzman DM, Crystal RG, Paul SM. Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. Neurobiology of Aging. 44: 159-172. PMID 27318144 DOI: 10.1016/J.Neurobiolaging.2016.04.020  0.52
2016 Vos SJ, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC, Fagan AM, Benzinger TL. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiology of Aging. 44: 1-8. PMID 27318129 DOI: 10.1016/J.Neurobiolaging.2016.03.025  0.444
2016 Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, Aldea P, McConathy J, Holtzman DM, Cairns NJ, Morris JC, Fagan AM, Ances BM, Benzinger TL. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain : a Journal of Neurology. PMID 27286736 DOI: 10.1093/Brain/Aww139  0.447
2016 Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TL, et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Science Translational Medicine. 8: 338ra66. PMID 27169802 DOI: 10.1126/Scitranslmed.Aaf2362  0.497
2016 Holtzman DM, Carrillo MC, Hendrix JA, Bain LJ, Catafau AM, Gault LM, Goedert M, Mandelkow E, Mandelkow EM, Miller DS, Ostrowitzki S, Polydoro M, Smith S, Wittmann M, Hutton M. Tau: From research to clinical development. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 27154059 DOI: 10.1016/J.Jalz.2016.03.018  0.415
2016 Ju YS, Finn MB, Sutphen CL, Herries EM, Jerome GM, Ladenson JH, Crimmins DL, Fagan AM, Holtzman DM. Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid. Annals of Neurology. PMID 27129429 DOI: 10.1002/Ana.24672  0.581
2016 Roe CM, Barco PP, Head DM, Ghoshal N, Selsor N, Babulal GM, Fierberg R, Vernon EK, Shulman N, Johnson A, Fague S, Xiong C, Grant EA, Campbell A, Ott BR, ... Holtzman DM, et al. Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Disease and Associated Disorders. PMID 27128959 DOI: 10.1097/Wad.0000000000000154  0.456
2016 Ingber AP, Hassenstab J, Fagan AM, Benzinger TL, Grant EA, Holtzman DM, Morris JC, Roe CM. Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 27104893 DOI: 10.3233/Jad-150478  0.368
2016 Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, Cella M, Grutzendler J, DeMattos RB, Cirrito JR, Holtzman DM, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. The Journal of Experimental Medicine. PMID 27091843 DOI: 10.1084/Jem.20151948  0.843
2016 Liu CC, Zhao N, Yamaguchi Y, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G. Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease. Science Translational Medicine. 8: 332ra44. PMID 27030596 DOI: 10.1126/Scitranslmed.Aad3650  0.737
2016 Tarawneh R, D'Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman DM. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. Jama Neurology. PMID 27018940 DOI: 10.1001/Jamaneurol.2016.0086  0.424
2016 Lee S, Viqar F, Zimmerman ME, Narkhede A, Tosto G, Benzinger TL, Marcus DS, Fagan AM, Goate A, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, et al. White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the Dominantly Inherited Alzheimer Network. Annals of Neurology. PMID 27016429 DOI: 10.1002/ana.24647  0.614
2016 Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, ... ... Holtzman DM, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 12: 292-323. PMID 27012484 DOI: 10.1016/J.Jalz.2016.02.002  0.373
2016 Schindler SE, Holtzman DM. CSF sTREM2: marking the tipping point between preclinical AD and dementia? Embo Molecular Medicine. PMID 26976613 DOI: 10.15252/Emmm.201606245  0.491
2016 Hölttä M, Dean RA, Siemers E, Mawuenyega KG, Sigurdson W, May PC, Holtzman DM, Portelius E, Zetterberg H, Bateman RJ, Blennow K, Gobom J. A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans. Alzheimer's Research & Therapy. 8: 11. PMID 26948580 DOI: 10.1186/S13195-016-0178-X  0.622
2016 Simonovitch S, Schmukler E, Bespalko A, Iram T, Frenkel D, Holtzman DM, Masliah E, Michaelson DM, Pinkas-Kramarski R. Impaired Autophagy in APOE4 Astrocytes. Journal of Alzheimer's Disease : Jad. PMID 26923027 DOI: 10.3233/Jad-151101  0.506
2016 Harris RA, Tindale L, Lone A, Singh O, Macauley SL, Stanley M, Holtzman DM, Bartha R, Cumming RC. Aerobic Glycolysis in the Frontal Cortex Correlates with Memory Performance in Wild-Type Mice But Not the APP/PS1 Mouse Model of Cerebral Amyloidosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 1871-8. PMID 26865611 DOI: 10.1523/Jneurosci.3131-15.2016  0.42
2016 Ulrich JD, Holtzman DM. TREM2 Function in Alzheimer's disease and neurodegeneration. Acs Chemical Neuroscience. PMID 26854967 DOI: 10.1021/Acschemneuro.5B00313  0.524
2016 Piccio L, Deming Y, Del-Águila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathologica. PMID 26754641 DOI: 10.1007/S00401-016-1533-5  0.323
2016 Ghosal K, Haag M, Verghese PB, West T, Veenstra T, Braunstein JB, Bateman RJ, Holtzman DM, Landreth GE. A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2: 110-120. DOI: 10.1016/j.trci.2016.06.001  0.816
2016 Petros J, Hassenstab J, Snitz BE, Zhou Y, Ringman JM, McDade E, Wang G, Balota DA, Aschenbrenner AJ, Benzinger TL, Cruchaga C, Fagan AM, Goate AM, Holtzman DM, Buckles V, et al. Dynamic Relationships Between “Big Five” Personality Traits, Alzheimer’S Disease Biomarkers, And Cognition In Autosomal Dominant Alzheimer’S Disease Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.970  0.514
2016 Pankiewicz J, Baquero-Buitrago J, Sanchez S, Lopez-Contreras J, Zaim-Wadghiri Y, Hoang MD, Bard F, Kim J, Sullivan PM, Holtzman DM, Sadowski MJ. Apolipoprotein E Genotype Differentially Modulates Effects Of Anti-Ab Immunotherapy Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.716  0.55
2016 McDade E, Weng H, Wang G, Xiong C, Fagan AM, Hassenstab J, Marcus DS, Morris JC, Benzinger TL, Cairns NJ, Goate AM, Buckles V, Holtzman DM, Berman S, Ghetti B, et al. O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network Alzheimer's & Dementia. 12: P378-P379. DOI: 10.1016/J.Jalz.2016.06.710  0.579
2016 Lim YY, Hassenstab J, Cruchaga C, Goate AM, Fagan AM, Lee Smith Benzinger T, Maruff P, Snyder PJ, Masters CL, Ricardo A, Chhatwal JP, Farlow MR, Graff-Radford NR, Laske C, Levin J, ... ... Holtzman DM, et al. F5-02-03: BDNF VAL66MET Moderates Cognitive Impairment, Neuronal Dysfunction and TAU in Preclinical Autosomal Dominant Alzheimer's Disease Alzheimer's & Dementia. 12: P369-P369. DOI: 10.1016/J.Jalz.2016.06.689  0.57
2016 Deming Y, Harari O, Black K, Carrell D, Cai Y, Del-Aguila JL, Fernandez V, Budde J, Ma S, Saef B, Bertelsen S, Kauwe J, Fagan AM, Holtzman DM, Morris JC, et al. Cerebrospinal Fluid Levels Of Amyloid Beta And Tau As Endophenotypes Reveal Novel Variants Potentially Informative For Alzheimer'S Disease Alzheimers & Dementia. 12: 252. DOI: 10.1016/J.Jalz.2016.06.452  0.449
2016 Wang Y, Ulland T, Ulrich JD, Song W, Yuan P, Mahan TE, Shi Y, Gilfillan S, Cella M, DeMattos RB, Grutzendler J, Cirrito JR, Holtzman DM, Colonna M. O2-07-02: Trem2-Mediated Early Response by Resident Microglia Limits Diffusion and Toxicity of Amyloid Plaques Alzheimer's & Dementia. 12: P241-P242. DOI: 10.1016/J.Jalz.2016.06.431  0.787
2016 Lee S, Zimmerman ME, Viqar F, Narkhede A, Tosto G, Lee Smith Benzinger T, Marcus DS, Goate AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, et al. O2-03-02: are White Matter Hyperintensities a Core Feature of Alzheimer’s Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN) Alzheimer's & Dementia. 12: P226-P226. DOI: 10.1016/J.Jalz.2016.06.406  0.574
2016 Gordon BA, Blazey T, Morris JC, Holtzman DM, Fagan AM, Benzinger TL. O1-07-04: Longitudinal Amyloid Deposition and Hippocampal Volume in Suspected Non-Alzheimer Pathophysiology and Preclinical Alzheimer's Disease Alzheimer's & Dementia. 12: P191-P191. DOI: 10.1016/J.Jalz.2016.06.332  0.469
2016 Holtzman DM. PL-01-01: Preclinical to Clinical Translation for TAU Therapeutics Alzheimer's & Dementia. 12: P169-P169. DOI: 10.1016/J.Jalz.2016.06.291  0.311
2016 Ances B, Brier MR, Gordon BA, Friedrichsen KA, McCarthy JE, Stern A, Christensen J, Owen CJ, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, et al. IC-P-179: TAU Imaging Relationships With Amyloid B Imaging, CSF TAU/AB42 , and Cognition in Alzheimer’s Disease Alzheimer's & Dementia. 12: P130-P131. DOI: 10.1016/J.Jalz.2016.06.210  0.361
2016 Gordon BA, Xiong C, Holtzman DM, Fagan AM, Morris JC, Benzinger TL. IC-P-139: Critical Analysis of Biomarker Cutoffs in Alzheimer Disease Alzheimer's & Dementia. 12: P103-P104. DOI: 10.1016/J.Jalz.2016.06.169  0.351
2016 Gordon BA, Friedrichsen KA, Brier MR, Blazey T, Su Y, Christensen J, McConathy J, Aldea P, Holtzman DM, Cairns NJ, Morris JC, Fagan AM, Ances B, Benzinger TL. P1-263: Relating PET and CSF Measure of TAU Pathology Alzheimer's & Dementia. 12: P513-P514. DOI: 10.1016/J.Jalz.2016.06.1012  0.329
2015 Leung YY, Toledo JB, Nefedov A, Polikar R, Raghavan N, Xie SX, Farnum M, Schultz T, Baek Y, Deerlin VV, Hu WT, Holtzman DM, Fagan AM, Perrin RJ, Grossman M, et al. Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. Alzheimer's & Dementia (Amsterdam, Netherlands). 1: 339-348. PMID 26693175 DOI: 10.1016/J.Dadm.2015.06.008  0.714
2015 Tambini MD, Pera M, Kanter E, Yang H, Guardia-Laguarta C, Holtzman D, Sulzer D, Area-Gomez E, Schon EA. ApoE4 upregulates the activity of mitochondria-associated ER membranes. Embo Reports. PMID 26564908 DOI: 10.15252/Embr.201540614  0.425
2015 Moore KM, Girens RE, Larson SK, Jones MR, Restivo JL, Holtzman DM, Cirrito JR, Yuede CM, Zimmerman SD, Timson BF. A spectrum of exercise training reduces soluble Aβ in a dose-dependent manner in a mouse model of Alzheimer's disease. Neurobiology of Disease. PMID 26563933 DOI: 10.1016/J.Nbd.2015.11.004  0.631
2015 Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, Holtzman DM. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathologica Communications. 3: 70. PMID 26556230 DOI: 10.1186/S40478-015-0250-Y  0.496
2015 Kim J, Yoon H, Horie T, Burchett JM, Restivo JL, Rotllan N, Ramírez CM, Verghese PB, Ihara M, Hoe HS, Esau C, Fernández-Hernando C, Holtzman DM, Cirrito JR, Ono K, et al. microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 14717-26. PMID 26538644 DOI: 10.1523/Jneurosci.2053-15.2015  0.829
2015 Yamada K, Patel TK, Hochgräfe K, Mahan TE, Jiang H, Stewart FR, Mandelkow EM, Holtzman DM. Analysis of in vivo turnover of tau in a mouse model of tauopathy. Molecular Neurodegeneration. 10: 55. PMID 26502977 DOI: 10.1186/S13024-015-0052-5  0.437
2015 Ulrich JD, Huynh TP, Holtzman DM. Re-evaluation of the Blood-Brain Barrier in the Presence of Alzheimer's Disease Pathology. Neuron. 88: 237-9. PMID 26494271 DOI: 10.1016/J.Neuron.2015.10.008  0.38
2015 Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimer's Research & Therapy. 7: 59. PMID 26383836 DOI: 10.1186/S13195-015-0142-1  0.341
2015 Zhu L, Zhong M, Elder GA, Sano M, Holtzman DM, Gandy S, Cardozo C, Haroutunian V, Robakis NK, Cai D. Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 112: 11965-70. PMID 26372964 DOI: 10.1073/Pnas.1510011112  0.503
2015 Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. Jama Neurology. 1-7. PMID 26366630 DOI: 10.1001/Jamaneurol.2015.1867  0.338
2015 Ising C, Stanley M, Holtzman DM. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development. Clinical Pharmacology and Therapeutics. 98: 469-71. PMID 26250900 DOI: 10.1002/Cpt.200  0.526
2015 Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, et al. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. Jama Neurology. 72: 1029-1042. PMID 26147946 DOI: 10.1001/Jamaneurol.2015.1285  0.453
2015 Macauley SL, Holtzman DM. Recent Advances from the Bench Toward the Bedside in Alzheimer's Disease. Ebiomedicine. 2: 94-5. PMID 26137544 DOI: 10.1016/J.Ebiom.2015.01.002  0.507
2015 Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI. Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake. The Journal of Biological Chemistry. 290: 21652-62. PMID 26126828 DOI: 10.1074/Jbc.M115.657924  0.417
2015 Lucey BP, Holtzman DM. How amyloid, sleep and memory connect. Nature Neuroscience. 18: 933-4. PMID 26108720 DOI: 10.1038/Nn.4048  0.318
2015 Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, Xiong C, Chott R, Yarasheski K, Sigurdson W, Zhang L, Goate A, Benzinger T, Morris JC, Holtzman D, et al. Age and amyloid effects on human CNS amyloid-beta kinetics. Annals of Neurology. PMID 26040676 DOI: 10.1002/Ana.24454  0.608
2015 Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nature Neuroscience. 18: 800-6. PMID 26007213 DOI: 10.1038/Nn.4018  0.497
2015 Yan P, Zhu A, Liao F, Xiao Q, Kraft AW, Gonzales E, Perez R, Greenberg SM, Holtzman DM, Lee JM. Minocycline reduces spontaneous hemorrhage in mouse models of cerebral amyloid angiopathy. Stroke; a Journal of Cerebral Circulation. 46: 1633-40. PMID 25944329 DOI: 10.1161/Strokeaha.115.008582  0.365
2015 Macauley SL, Stanley M, Caesar EE, Yamada SA, Raichle ME, Perez R, Mahan TE, Sutphen CL, Holtzman DM. Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo. The Journal of Clinical Investigation. 125: 2463-7. PMID 25938784 DOI: 10.1172/Jci79742  0.425
2015 Yamamoto K, Tanei Z, Hashimoto T, Wakabayashi T, Okuno H, Naka Y, Yizhar O, Fenno LE, Fukayama M, Bito H, Cirrito JR, Holtzman DM, Deisseroth K, Iwatsubo T. Chronic optogenetic activation augments aβ pathology in a mouse model of Alzheimer disease. Cell Reports. 11: 859-65. PMID 25937280 DOI: 10.1016/J.Celrep.2015.04.017  0.682
2015 Liao F, Jiang H, Srivatsan S, Xiao Q, Lefton KB, Yamada K, Mahan TE, Lee JM, Shaw AS, Holtzman DM. Effects of CD2-associated protein deficiency on amyloid-β in neuroblastoma cells and in an APP transgenic mouse model. Molecular Neurodegeneration. 10: 12. PMID 25887956 DOI: 10.1186/S13024-015-0006-Y  0.459
2015 Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, Morris JC, Holtzman DM. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. Jama Neurology. 72: 656-65. PMID 25867677 DOI: 10.1001/Jamaneurol.2015.0202  0.429
2015 Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Annals of Clinical and Translational Neurology. 2: 278-88. PMID 25815354 DOI: 10.1002/Acn3.176  0.605
2015 Sahlholm K, Liao F, Holtzman DM, Xu J, Mach RH. Sigma-2 receptor binding is decreased in female, but not male, APP/PS1 mice. Biochemical and Biophysical Research Communications. 460: 439-45. PMID 25796326 DOI: 10.1016/J.Bbrc.2015.03.052  0.431
2015 Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Experimental & Molecular Medicine. 47: e148. PMID 25766617 DOI: 10.1038/Emm.2014.121  0.366
2015 Morales DM, Holubkov R, Inder TE, Ahn HC, Mercer D, Rao R, McAllister JP, Holtzman DM, Limbrick DD. Cerebrospinal fluid levels of amyloid precursor protein are associated with ventricular size in post-hemorrhagic hydrocephalus of prematurity. Plos One. 10: e0115045. PMID 25738507 DOI: 10.1371/Journal.Pone.0115045  0.327
2015 Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 160: 1061-71. PMID 25728668 DOI: 10.1016/J.Cell.2015.01.049  0.688
2015 Gordon BA, Zacks JM, Blazey T, Benzinger TL, Morris JC, Fagan AM, Holtzman DM, Balota DA. Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. Neurobiology of Aging. 36: 1771-9. PMID 25708908 DOI: 10.1016/J.Neurobiolaging.2015.01.019  0.393
2015 Han BH, Zhou ML, Johnson AW, Singh I, Liao F, Vellimana AK, Nelson JW, Milner E, Cirrito JR, Basak J, Yoo M, Dietrich HH, Holtzman DM, Zipfel GJ. Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice. Proceedings of the National Academy of Sciences of the United States of America. 112: E881-90. PMID 25675483 DOI: 10.1073/Pnas.1414930112  0.82
2015 Hyman BT, Holtzman DM. Apolipoprotein E levels and Alzheimer risk. Annals of Neurology. 77: 204-5. PMID 25583643 DOI: 10.1002/Ana.24355  0.351
2015 Aschenbrenner AJ, Balota DA, Tse CS, Fagan AM, Holtzman DM, Benzinger TL, Morris JC. Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. Neuropsychology. 29: 368-81. PMID 25222200 DOI: 10.1037/Neu0000133  0.414
2015 Liao F, Zhang TJ, Mahan TE, Jiang H, Holtzman DM. Effects of growth hormone-releasing hormone on sleep and brain interstitial fluid amyloid-β in an APP transgenic mouse model. Brain, Behavior, and Immunity. 47: 163-71. PMID 25218899 DOI: 10.1016/J.Bbi.2014.09.005  0.436
2015 Roh JH, Jiang H, Finn MB, Stewart FR, Mahan TE, Cirrito JR, Heda A, Joy Snider B, Li M, Yanagisawa M, de Lecea L, Holtzman DM. Correction to Potential role of orexin and sleep modulation in the pathogenesis of alzheimer's disease [The Journal of Experimental Medicine, 211, 13, (2014), 2487-2496] Journal of Experimental Medicine. 212: 121. DOI: 10.1084/Jem.2014178812122014C  0.623
2015 Ooms S, Zempel J, Holtzman D, Ju Y. Automated slow wave sleep disruption in middle-aged adults Sleep Medicine. 16: S16. DOI: 10.1016/J.Sleep.2015.02.037  0.504
2015 Kester MI, Teunissen CE, Crimmins DL, Macy EM, Ladenson JH, Scheltens P, Flier WMvd, Morris JC, Holtzman DM, Fagan AM. Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease Alzheimers & Dementia. 11: 326. DOI: 10.1016/J.Jalz.2015.07.471  0.405
2015 Perrin RJ, Weng H, Bales KR, Morris JC, Benzinger TL, Fagan AM, Xiong C, Holtzman DM. O3-14-03: Novel fluid biomarkers for brain amyloid and dementia risk in presymptomatic Alzheimer disease Alzheimer's & Dementia. 11: P255-P255. DOI: 10.1016/J.Jalz.2015.07.317  0.696
2015 Holtzman DM. F2-02-02: Effects of disrupted sleep on abeta and tau pathology and effects of abeta and tau pathology on sleep: A vicious cycle? Alzheimer's & Dementia. 11: P165-P166. DOI: 10.1016/J.Jalz.2015.07.113  0.336
2015 Roe CM, Barco PP, Head DM, Ghoshal N, Selsor N, Babulal GM, Fierberg R, Vernon EK, Shulman N, Johnson A, Fague MS, Xiong C, Grant E, Campbell A, Holtzman DM, et al. P2-130: Amyloid imaging and cerebrospinal fluid biomarkers predict driving performance in preclinical Alzheimer's disease Alzheimer's & Dementia. 11: P533-P534. DOI: 10.1016/J.Jalz.2015.06.668  0.418
2015 Huff MJ, Balota DA, Aschenbrenner AJ, Duchek JM, Fagan AM, Holtzman DM, Benzinger TL, Morris JC. P2-085: Task-switching errors show sensitivity to preclinical Alzheimer's disease biomarkers Alzheimer's & Dementia. 11: P516-P516. DOI: 10.1016/J.Jalz.2015.06.622  0.333
2015 Gordon BA, Vos S, Morris JC, Holtzman DM, Fagan AM, Benzinger TL. IC-P-020: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers Alzheimer's & Dementia. 11: P24-P25. DOI: 10.1016/J.Jalz.2015.06.040  0.364
2015 Leung YY, Toledo JB, Nefedov A, Polikar R, Raghavan N, Xie SX, Farnum M, Schultz T, Baek Y, Deerlin VV, Hu WT, Holtzman DM, Fagan AM, Perrin RJ, Grossman M, et al. Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 1: 339-348. DOI: 10.1016/j.dadm.2015.06.008  0.672
2014 Roh JH, Jiang H, Finn MB, Stewart FR, Mahan TE, Cirrito JR, Heda A, Snider BJ, Li M, Yanagisawa M, de Lecea L, Holtzman DM. Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease. The Journal of Experimental Medicine. 211: 2487-96. PMID 25422493 DOI: 10.1084/Jem.20141788  0.648
2014 Lim MM, Gerstner JR, Holtzman DM. The sleep-wake cycle and Alzheimer's disease: what do we know? Neurodegenerative Disease Management. 4: 351-62. PMID 25405649 DOI: 10.2217/Nmt.14.33  0.636
2014 Kauwe JS, Bailey MH, Ridge PG, Perry R, Wadsworth ME, Hoyt KL, Staley LA, Karch CM, Harari O, Cruchaga C, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, ... ... Holtzman DM, et al. Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. Plos Genetics. 10: e1004758. PMID 25340798 DOI: 10.1371/Journal.Pgen.1004758  0.334
2014 Dikranian K, Holtzman DM. The Ultrastructural Identity of Alzheimer's Pathology: Lessons from Animal Models. Journal of Neurological Disorders. 2: e111. PMID 25309943 DOI: 10.4172/2329-6895.1000E111  0.495
2014 Liao F, Holtzman DM. Human neurons derived from induced pluripotent stem cells as a new platform for preclinical drug screening and development. Jama Neurology. 71: 1475-6. PMID 25285675 DOI: 10.1001/Jamaneurol.2014.2802  0.477
2014 Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, Belaygorod L, Cairns NJ, Holtzman DM, Diamond MI. Proteopathic tau seeding predicts tauopathy in vivo. Proceedings of the National Academy of Sciences of the United States of America. 111: E4376-85. PMID 25261551 DOI: 10.1073/Pnas.1411649111  0.426
2014 Garai K, Verghese PB, Baban B, Holtzman DM, Frieden C. The binding of apolipoprotein E to oligomers and fibrils of amyloid-β alters the kinetics of amyloid aggregation. Biochemistry. 53: 6323-31. PMID 25207746 DOI: 10.1021/Bi5008172  0.786
2014 Milner E, Zhou ML, Johnson AW, Vellimana AK, Greenberg JK, Holtzman DM, Han BH, Zipfel GJ. Cerebral amyloid angiopathy increases susceptibility to infarction after focal cerebral ischemia in Tg2576 mice. Stroke; a Journal of Cerebral Circulation. 45: 3064-9. PMID 25190447 DOI: 10.1161/Strokeaha.114.006078  0.428
2014 Thomas JB, Brier MR, Bateman RJ, Snyder AZ, Benzinger TL, Xiong C, Raichle M, Holtzman DM, Sperling RA, Mayeux R, Ghetti B, Ringman JM, Salloway S, McDade E, Rossor MN, et al. Functional connectivity in autosomal dominant and late-onset Alzheimer disease. Jama Neurology. 71: 1111-22. PMID 25069482 DOI: 10.1001/Jamaneurol.2014.1654  0.582
2014 Pankiewicz JE, Guridi M, Kim J, Asuni AA, Sanchez S, Sullivan PM, Holtzman DM, Sadowski MJ. Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice. Acta Neuropathologica Communications. 2: 75. PMID 24972680 DOI: 10.1186/Preaccept-1147957959132865  0.71
2014 Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM. Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2. Molecular Neurodegeneration. 9: 20. PMID 24893973 DOI: 10.1186/1750-1326-9-20  0.457
2014 Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J, Culver JP, Betensky R, Wozniak DF, Hyman BT, Holtzman DM. Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 7281-92. PMID 24849360 DOI: 10.1523/Jneurosci.0646-14.2014  0.772
2014 Shin S, Walz KA, Archambault AS, Sim J, Bollman BP, Koenigsknecht-Talboo J, Cross AH, Holtzman DM, Wu GF. Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis. Journal of Neuroimmunology. 271: 8-17. PMID 24794230 DOI: 10.1016/J.Jneuroim.2014.03.010  0.36
2014 Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, ... Holtzman DM, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Science Translational Medicine. 6: 226ra30. PMID 24598588 DOI: 10.1126/Scitranslmed.3007901  0.642
2014 Harari O, Cruchaga C, Kauwe JS, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Goate AM. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Biological Psychiatry. 75: 723-31. PMID 24548642 DOI: 10.1016/J.Biopsych.2013.11.032  0.437
2014 Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgräfe K, Mandelkow EM, Holtzman DM. Neuronal activity regulates extracellular tau in vivo. The Journal of Experimental Medicine. 211: 387-93. PMID 24534188 DOI: 10.1085/Jgp.1434Oia12  0.639
2014 Caglayan S, Takagi-Niidome S, Liao F, Carlo AS, Schmidt V, Burgert T, Kitago Y, Füchtbauer EM, Füchtbauer A, Holtzman DM, Takagi J, Willnow TE. Lysosomal sorting of amyloid-β by the SORLA receptor is impaired by a familial Alzheimer's disease mutation. Science Translational Medicine. 6: 223ra20. PMID 24523320 DOI: 10.1126/Scitranslmed.3007747  0.497
2014 Benitez BA, Jin SC, Guerreiro R, Graham R, Lord J, Harold D, Sims R, Lambert JC, Gibbs JR, Bras J, Sassi C, Harari O, Bertelsen S, Lupton MK, Powell J, ... ... Holtzman DM, et al. Missense variant in TREML2 protects against Alzheimer's disease. Neurobiology of Aging. 35: 1510.e19-26. PMID 24439484 DOI: 10.1016/J.Neurobiolaging.2013.12.010  0.418
2014 Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology--a bidirectional relationship. Nature Reviews. Neurology. 10: 115-9. PMID 24366271 DOI: 10.1038/Nrneurol.2013.269  0.387
2014 Brier MR, Thomas JB, Fagan AM, Hassenstab J, Holtzman DM, Benzinger TL, Morris JC, Ances BM. Functional connectivity and graph theory in preclinical Alzheimer's disease. Neurobiology of Aging. 35: 757-68. PMID 24216223 DOI: 10.1016/J.Neurobiolaging.2013.10.081  0.454
2014 Sutphen CL, Fagan AM, Holtzman DM. Progress update: fluid and imaging biomarkers in Alzheimer's disease. Biological Psychiatry. 75: 520-6. PMID 24012326 DOI: 10.1016/J.Biopsych.2013.07.031  0.433
2014 Sutphen CL, Shah AR, Jasielec M, Xiong C, Vlassenko AG, Benzinger T, Stoops E, Vanderstichele H, Brix B, Darby H, Leen Jef Vandijck M, Ladenson JH, Holtzman D, Morris JC, Fagan AM. P1-143: LONGITUDINAL CHANGES IN CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE: FINDINGS FROM A COGNITIVELY NORMAL, MIDDLE-AGED COHORT Alzheimer's & Dementia. 10: P352-P353. DOI: 10.1016/J.Jalz.2014.05.380  0.347
2014 Aschenbrenner AJ, Balota DA, Tse C, Fagan AM, Holtzman DM, Benzinger TL, Morris JC. P1-021: SYNERGISTIC AND MEDIATIONAL EFFECTS OF ALZHEIMER'S DISEASE BIOMARKERS ON A COGNITIVE MEASURE Alzheimer's & Dementia. 10: P311-P312. DOI: 10.1016/J.Jalz.2014.05.256  0.368
2014 Vlassenko AG, Fagan AM, Jasielec MS, Su Y, Xiong C, Holtzman DM, Benzinger TL, Morris JC. IC-P-008: REGIONAL PIB DEPOSITION AND CSF Aβ42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY Alzheimer's & Dementia. 10: P11-P11. DOI: 10.1016/J.Jalz.2014.05.012  0.385
2013 Jack CR, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron. 80: 1347-58. PMID 24360540 DOI: 10.1016/J.Neuron.2013.12.003  0.473
2013 Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Shinohara M, Holtzman DM, Bu G. Neuronal clearance of amyloid-β by endocytic receptor LRP1. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 19276-83. PMID 24305823 DOI: 10.1523/Jneurosci.3487-13.2013  0.705
2013 Musiek ES, Lim MM, Yang G, Bauer AQ, Qi L, Lee Y, Roh JH, Ortiz-Gonzalez X, Dearborn JT, Culver JP, Herzog ED, Hogenesch JB, Wozniak DF, Dikranian K, Giasson BI, ... ... Holtzman DM, et al. Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. The Journal of Clinical Investigation. 123: 5389-400. PMID 24270424 DOI: 10.1172/Jci70317  0.763
2013 Roe CM, Fagan AM, Grant EA, Holtzman DM, Morris JC. CSF biomarkers of Alzheimer disease: "noncognitive" outcomes. Neurology. 81: 2028-31. PMID 24212387 DOI: 10.1212/01.Wnl.0000436940.78152.05  0.39
2013 Lehtinen MK, Bjornsson CS, Dymecki SM, Gilbertson RJ, Holtzman DM, Monuki ES. The choroid plexus and cerebrospinal fluid: emerging roles in development, disease, and therapy. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 17553-9. PMID 24198345 DOI: 10.1523/Jneurosci.3258-13.2013  0.308
2013 Benzinger TL, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, ... ... Holtzman DM, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 110: E4502-9. PMID 24194552 DOI: 10.1073/Pnas.1317918110  0.559
2013 Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 80: 402-14. PMID 24075978 DOI: 10.1016/J.Neuron.2013.07.046  0.629
2013 Duchek JM, Balota DA, Thomas JB, Snyder AZ, Rich P, Benzinger TL, Fagan AM, Holtzman DM, Morris JC, Ances BM. Relationship between Stroop performance and resting state functional connectivity in cognitively normal older adults. Neuropsychology. 27: 516-28. PMID 24040929 DOI: 10.1037/A0033402  0.358
2013 Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. The Lancet. Neurology. 12: 957-65. PMID 24012374 DOI: 10.1016/S1474-4422(13)70194-7  0.43
2013 Benitez BA, Karch CM, Cai Y, Jin SC, Cooper B, Carrell D, Bertelsen S, Chibnik L, Schneider JA, Bennett DA, Fagan AM, Holtzman D, Morris JC, et al. The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers. Plos Genetics. 9: e1003685. PMID 23990795 DOI: 10.1371/Journal.Pgen.1003685  0.392
2013 Wang L, Brier MR, Snyder AZ, Thomas JB, Fagan AM, Xiong C, Benzinger TL, Holtzman DM, Morris JC, Ances BM. Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity. Jama Neurology. 70: 1242-8. PMID 23959173 DOI: 10.1001/Jamaneurol.2013.3253  0.348
2013 Ju YE, Holtzman DM. Sleep evaluation by actigraphy for patients with Alzheimer disease--reply. Jama Neurology. 70: 1074-5. PMID 23939592 DOI: 10.1001/Jamaneurol.2013.3490  0.317
2013 DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, Schuler DR, Maloney SE, Wozniak DF, Rigo F, Bennett CF, Cirrito JR, Holtzman DM, Miller TM. Antisense reduction of tau in adult mice protects against seizures. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 12887-97. PMID 23904623 DOI: 10.1523/Jneurosci.2107-13.2013  0.732
2013 Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TL, Bateman RJ. Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Science Translational Medicine. 5: 189ra77. PMID 23761040 DOI: 10.1126/Scitranslmed.3005615  0.595
2013 Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science (New York, N.Y.). 340: 924-f. PMID 23704555 DOI: 10.1126/Science.1235505  0.472
2013 Perrin RJ, Payton JE, Malone JP, Gilmore P, Davis AE, Xiong C, Fagan AM, Townsend RR, Holtzman DM. Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation. Plos One. 8: e64314. PMID 23700471 DOI: 10.1371/Journal.Pone.0064314  0.565
2013 Zhang YH, Raymick J, Sarkar S, Lahiri DK, Ray B, Holtzman D, Dumas M, Schmued LC. Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease. Current Alzheimer Research. 10: 494-506. PMID 23627708 DOI: 10.2174/1567205011310050005  0.509
2013 Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proceedings of the National Academy of Sciences of the United States of America. 110: E1807-16. PMID 23620513 DOI: 10.1073/Pnas.1220484110  0.833
2013 Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, Landreth GE, Castellano JM, Jiang H, Cirrito JR, Holtzman DM. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Molecular Neurodegeneration. 8: 13. PMID 23601557 DOI: 10.1186/1750-1326-8-13  0.834
2013 Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, ... ... Holtzman DM, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron. 78: 256-68. PMID 23562540 DOI: 10.1016/J.Neuron.2013.02.026  0.414
2013 Kuszczyk MA, Sanchez S, Pankiewicz J, Kim J, Duszczyk M, Guridi M, Asuni AA, Sullivan PM, Holtzman DM, Sadowski MJ. Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration. The American Journal of Pathology. 182: 1750-68. PMID 23499462 DOI: 10.1016/J.Ajpath.2013.01.034  0.654
2013 Ju YE, McLeland JS, Toedebusch CD, Xiong C, Fagan AM, Duntley SP, Morris JC, Holtzman DM. Sleep quality and preclinical Alzheimer disease. Jama Neurology. 70: 587-93. PMID 23479184 DOI: 10.1001/Jamaneurol.2013.2334  0.34
2013 Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL. Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Annals of Neurology. 73: 104-19. PMID 23225543 DOI: 10.1002/Ana.23748  0.756
2013 Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, Holtzman DM, Wancewicz E, Bennett CF, Bowser R, Cudkowicz M, Miller TM. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. Jama Neurology. 70: 201-7. PMID 23147550 DOI: 10.1001/Jamaneurol.2013.593  0.364
2013 Kraft AW, Hu X, Yoon H, Yan P, Xiao Q, Wang Y, Gil SC, Brown J, Wilhelmsson U, Restivo JL, Cirrito JR, Holtzman DM, Kim J, Pekny M, Lee JM. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 27: 187-98. PMID 23038755 DOI: 10.1096/Fj.12-208660  0.84
2013 Wang L, Brier M, Snyder A, Thomas J, Fagan A, Xiong C, Benzinger T, Holtzman D, Morris J, Ances B. P2-159: Cerebrospinal fluid beta-amyloid 42, tau, phosphorylated tau 181, and resting state functional connectivity Alzheimer's & Dementia. 9: P405-P406. DOI: 10.1016/J.Jalz.2013.05.804  0.378
2013 Shah A, Sutphen C, Amos M, Althage M, Morris J, Holtzman D, Fagan A. Evaluation of pre-analytical and analytical factors that contribute to variability in CSF biomarker levels Alzheimers & Dementia. 9: 211. DOI: 10.1016/J.Jalz.2013.05.393  0.328
2013 Cruchaga C, Harari O, Kauwe J, Bales K, Pickering EH, Bertelsen S, Fagan A, Holtzman D, Morris J, Goate A. P4-002: Cerebrospinal heart fatty-acid-binding protein as a biomarker for Alzheimer's disease Alzheimer's & Dementia. 9: P705-P705. DOI: 10.1016/J.Jalz.2013.05.1390  0.341
2013 Wang L, Brier M, Snyder A, Thomas J, Fagan A, Xiong C, Benzinger T, Holtzman D, Morris J, Ances B. IC-P-113: Cerebrospinal fluid beta-amyloid 42, tau, ptau181 and resting state functional connectivity Alzheimer's & Dementia. 9: P68-P69. DOI: 10.1016/J.Jalz.2013.05.110  0.348
2013 Brier M, Thomas J, Fagan A, Holtzman D, Benzinger T, Morris J, Ances B. IC-P-085: Early pathological changes due to Alzheimer's disease are detected by graph theoretical measures of functional connectivity Alzheimer's & Dementia. 9: P50-P50. DOI: 10.1016/J.Jalz.2013.05.082  0.331
2013 Vos S, Xiong C, Grant E, Visser PJ, Cairns N, Morris J, Holtzman D, Fagan A. O4-02-03: Using cerebrospinal fluid markers to identify stages of National Institute on Aging and Alzheimer's Association proposed criteria for preclinical Alzheimer's disease and its prognosis Alzheimer's & Dementia. 9: P682-P682. DOI: 10.1016/J.Jalz.2013.04.342  0.389
2013 Benitez B, Karch C, Jin SC, Carrel D, Cooper B, Bertelsen S, Morris J, Holtzman D, Goate A, Cruchaga C. Rare variants in APP and PSEN1 genes associated with extreme levels of beta-amyloid 42 and tau protein in cerebrospinal fluid Alzheimers & Dementia. 9: 680. DOI: 10.1016/J.Jalz.2013.04.338  0.39
2013 Roh JH, Heda A, Finn MB, Mahan T, Li M, Nishino S, Holtzman D. Potential role of orexin in the pathogenesis of Alzheimer's disease Alzheimers & Dementia. 9: 521. DOI: 10.1016/J.Jalz.2013.04.246  0.409
2013 Pankiewicz J, Kim J, Ormazabal MG, Sanchez S, Granovetter M, Sullivan P, Holtzman D, Sadowski M. O1-11-05: Pharmacological inhibition of the beta-amyloid and apolipoprotein E interaction ameliorates Alzheimer's pathology in APPSW/PS1dE9 / APOE-ε2-TR and APPSW/PS1dE9 / APOE-ε4-TR mice Alzheimer's & Dementia. 9: P152-P153. DOI: 10.1016/J.Jalz.2013.04.114  0.55
2013 Leung YY, Toledo J, Nefedov A, Polikar R, Raghavan N, Xie S, Farnum M, Schultz T, Baek Y, Lobanov V, DiBernardo A, Deerlin VV, Kling M, Chen-Plotkin A, Mailman M, ... ... Holtzman D, et al. Identifying multi-analyte CSF biomarkers for Alzheimer’s disease in a multi-cohort study Alzheimers & Dementia. 9. DOI: 10.1016/J.Jalz.2013.04.059  0.62
2012 Roh JH, Holtzman DM. Stealth attack: plaque-specific antibody allows for efficient Aβ removal without side effects. Neuron. 76: 859-61. PMID 23217733 DOI: 10.1016/J.Neuron.2012.11.018  0.402
2012 Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clinical Investigation. 2: 975-984. PMID 23139856 DOI: 10.4155/Cli.12.93  0.552
2012 Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis. The Journal of Experimental Medicine. 209: 2149-56. PMID 23129750 DOI: 10.1084/Jem.20121274  0.832
2012 Holtzman DM, Mandelkow E, Selkoe DJ. Alzheimer disease in 2020. Cold Spring Harbor Perspectives in Medicine. 2. PMID 23125202 DOI: 10.1101/Cshperspect.A011585  0.397
2012 Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, Mitani A, Joyner D, Thyssen DH, Bacskai BJ, Frosch MP, Spires-Jones TL, Finn MB, Holtzman DM, Hyman BT. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 15181-92. PMID 23100439 DOI: 10.1523/Jneurosci.1542-12.2012  0.518
2012 Musiek ES, Holtzman DM. Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Current Opinion in Neurology. 25: 715-20. PMID 23041958 DOI: 10.1097/Wco.0B013E32835A30F4  0.488
2012 Xiao Q, Ford AL, Xu J, Yan P, Lee KY, Gonzales E, West T, Holtzman DM, Lee JM. Bcl-x pre-mRNA splicing regulates brain injury after neonatal hypoxia-ischemia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 13587-96. PMID 23015448 DOI: 10.1523/Jneurosci.2617-12.2012  0.517
2012 Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM. Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Science Translational Medicine. 4: 150ra122. PMID 22956200 DOI: 10.1126/Scitranslmed.3004291  0.81
2012 Dikranian K, Kim J, Stewart FR, Levy MA, Holtzman DM. Ultrastructural studies in APP/PS1 mice expressing human ApoE isoforms: implications for Alzheimer's disease. International Journal of Clinical and Experimental Pathology. 5: 482-95. PMID 22949930  0.683
2012 Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proceedings of the National Academy of Sciences of the United States of America. 109: 15502-7. PMID 22927427 DOI: 10.1073/Pnas.1206446109  0.819
2012 Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 79: 897-905. PMID 22855860 DOI: 10.1212/Wnl.0B013E318266Fa70  0.823
2012 Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, Bertelsen S, Hinrichs A, Fagan AM, Holtzman DM, Morris JC, Goate AM. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Human Molecular Genetics. 21: 4558-71. PMID 22821396 DOI: 10.1093/Hmg/Dds296  0.399
2012 Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. The New England Journal of Medicine. 367: 795-804. PMID 22784036 DOI: 10.1056/Nejmoa1202753  0.593
2012 Brier MR, Thomas JB, Snyder AZ, Benzinger TL, Zhang D, Raichle ME, Holtzman DM, Morris JC, Ances BM. Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 8890-9. PMID 22745490 DOI: 10.1523/Jneurosci.5698-11.2012  0.425
2012 Hunter JM, Cirrito JR, Restivo JL, Kinley RD, Sullivan PM, Holtzman DM, Koger D, Delong C, Lin S, Zhao L, Liu F, Bales K, Paul SM. Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice. Brain Research. 1467: 120-32. PMID 22682924 DOI: 10.1016/J.Brainres.2012.05.048  0.634
2012 Wildsmith KR, Basak JM, Patterson BW, Pyatkivskyy Y, Kim J, Yarasheski KE, Wang JX, Mawuenyega KG, Jiang H, Parsadanian M, Yoon H, Kasten T, Sigurdson WC, Xiong C, Goate A, ... Holtzman DM, et al. In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. Plos One. 7: e38013. PMID 22675504 DOI: 10.1371/Journal.Pone.0038013  0.84
2012 Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D, Hou S, Kopeikina KJ, Frosch MP, Lee VM, Holtzman DM, Hyman BT, Spires-Jones TL. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain : a Journal of Neurology. 135: 2155-68. PMID 22637583 DOI: 10.1093/Brain/Aws127  0.47
2012 Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 485: 512-6. PMID 22622580 DOI: 10.1038/Nature11087  0.443
2012 Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harbor Perspectives in Medicine. 2: a006148. PMID 22553492 DOI: 10.1101/Cshperspect.A006148  0.405
2012 Hata S, Taniguchi M, Piao Y, Ikeuchi T, Fagan AM, Holtzman DM, Bateman R, Sohrabi HR, Martins RN, Gandy S, Urakami K, Suzuki T. Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects. Molecular Neurodegeneration. 7: 16. PMID 22534039 DOI: 10.1186/1750-1326-7-16  0.594
2012 Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, Andreasson U, Siemers E, Mawuenyega KG, Sigurdson WC, May PC, Paul SM, Holtzman DM, Blennow K, Bateman RJ. Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 31: 335-41. PMID 22531418 DOI: 10.3233/Jad-2012-120508  0.59
2012 Holtzman DM. CSF biomarkers for secondary prevention trials: why markers of amyloid deposition and neurodegeneration are both important. Archives of Neurology. 69: 691-2. PMID 22529246 DOI: 10.1001/Archneurol.2012.587  0.39
2012 Basak JM, Kim J, Pyatkivskyy Y, Wildsmith KR, Jiang H, Parsadanian M, Patterson BW, Bateman RJ, Holtzman DM. Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling. Molecular Neurodegeneration. 7: 14. PMID 22512932 DOI: 10.1186/1750-1326-7-14  0.825
2012 Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. The Journal of Biological Chemistry. 287: 19440-51. PMID 22461630 DOI: 10.1074/Jbc.M112.346072  0.411
2012 Bero AW, Bauer AQ, Stewart FR, White BR, Cirrito JR, Raichle ME, Culver JP, Holtzman DM. Bidirectional relationship between functional connectivity and amyloid-β deposition in mouse brain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 4334-40. PMID 22457485 DOI: 10.1523/Jneurosci.5845-11.2012  0.826
2012 McDonald JM, Cairns NJ, Taylor-Reinwald L, Holtzman D, Walsh DM. The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain. Brain Research. 1450: 138-47. PMID 22440675 DOI: 10.1016/J.Brainres.2012.02.041  0.436
2012 Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2: a006312. PMID 22393530 DOI: 10.1101/Cshperspect.A006312  0.445
2012 Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM. Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes. The Journal of Biological Chemistry. 287: 13959-71. PMID 22383525 DOI: 10.1074/Jbc.M111.288746  0.814
2012 Selkoe D, Mandelkow E, Holtzman D. Deciphering Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2: a011460. PMID 22315723 DOI: 10.1101/Cshperspect.A011460  0.398
2012 Storandt M, Head D, Fagan AM, Holtzman DM, Morris JC. Toward a multifactorial model of Alzheimer disease. Neurobiology of Aging. 33: 2262-71. PMID 22261556 DOI: 10.1016/J.Neurobiolaging.2011.11.029  0.461
2012 Ances BM, Benzinger TL, Christensen JJ, Thomas J, Venkat R, Teshome M, Aldea P, Fagan AM, Holtzman DM, Morris JC, Clifford DB. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Archives of Neurology. 69: 72-7. PMID 22232345 DOI: 10.1001/Archneurol.2011.761  0.361
2012 Head D, Bugg JM, Goate AM, Fagan AM, Mintun MA, Benzinger T, Holtzman DM, Morris JC. Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. Archives of Neurology. 69: 636-43. PMID 22232206 DOI: 10.1001/Archneurol.2011.845  0.373
2012 Jiang M, Wang J, Fu J, Du L, Jeong H, West T, Xiang L, Peng Q, Hou Z, Cai H, Seredenina T, Arbez N, Zhu S, Sommers K, Qian J, ... ... Holtzman DM, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nature Medicine. 18: 153-8. PMID 22179319 DOI: 10.1038/Nm.2558  0.618
2012 Wang L, Fagan AM, Shah AR, Beg MF, Csernansky JG, Morris JC, Holtzman DM. Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type. Alzheimer Disease and Associated Disorders. 26: 314-21. PMID 22156755 DOI: 10.1097/Wad.0B013E31823C0Cf4  0.446
2012 Magnoni S, Esparza TJ, Conte V, Carbonara M, Carrabba G, Holtzman DM, Zipfel GJ, Stocchetti N, Brody DL. Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain : a Journal of Neurology. 135: 1268-80. PMID 22116192 DOI: 10.1093/Brain/Awr286  0.339
2012 Wildsmith KR, Basak JM, Patterson BW, Pyatkivskyy Y, Kim J, Yarasheski KE, Wang JX, Mawuenyega KG, Jiang H, Parsadanian M, Yoon H, Kasten T, Sigurdson WC, Xiong C, Goate A, ... Holtzman DM, et al. Correction: In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS Plos One. 7. DOI: 10.1371/Annotation/9Bd329B7-Cdea-45Ec-A4Aa-A173855Dc0B9  0.766
2012 Ju Y, Duntley S, Fagan A, Morris J, Holtzman D. Sleep Disruption and Risk of Preclinical Alzheimer Disease (P01.081) Neurology. 78: P01.081-P01.081. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P01.081  0.33
2012 Kim J, Eltorai A, Jiang H, Stewart F, Liao F, Holtzman DM. 36 Effect of Anti-ApoE antibodies on Aβ pathology and accumulation Neurobiology of Aging. 33: S16. DOI: 10.1016/J.Neurobiolaging.2012.01.054  0.371
2012 Brody D, Esparza T, Zhao H, Cirrito J, Cairns N, Bateman R, Holtzman D. P4-266: BETA-AMYLOID oligomerization in Alzheimer's DISEASE DEMENTIA versus high pathology controls Alzheimer's & Dementia. 8: S752-S752. DOI: 10.1016/J.Jalz.2013.08.047  0.749
2012 Cruchaga C, Goate A, Thompson P, Kauwe J, Mayo K, Bertelsen S, Hinrichs T, Fagan A, Holtzman D. F2-02-04: Genome-wide association studies using cerebrospinal fluid biomarkers as an endophenotype for Alzheimer's disease Alzheimer's & Dementia. 8: P232-P233. DOI: 10.1016/J.Jalz.2012.05.615  0.35
2012 Sutphen CL, Shah AR, Amos M, Vlassenko AG, Benzinger TL, Holtzman DM, Morris JC, Fagan AM. O1-01-06: Longitudinal changes in cerebrospinal fluid biomarkers of Alzheimer's disease during middle-age in cognitively normal individuals with a positive family history Alzheimer's & Dementia. 8: P86-P86. DOI: 10.1016/J.Jalz.2012.05.207  0.344
2012 Bateman R, Benzinger T, Cairns N, Fagan A, Goate A, Marcus D, Storandt M, Xiong C, Buckles V, Holtzman D, Moulder K, Oliver A, Santacruz A, Fox N, Ghetti B, et al. Presymptomatic Alzheimer's disease in the Dominantly Inherited Alzheimer's Network (DIAN) Alzheimers & Dementia. 8: 4. DOI: 10.1016/J.Jalz.2012.05.015  0.587
2011 Holtzman DM, Goate A, Kelly J, Sperling R. Mapping the road forward in Alzheimer's disease. Science Translational Medicine. 3: 114ps48. PMID 22190237 DOI: 10.1126/Scitranslmed.3003529  0.447
2011 Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 18007-12. PMID 22159114 DOI: 10.1523/Jneurosci.3773-11.2011  0.848
2011 Legleiter J, Fryer JD, Holtzman DM, Kowalewski A. The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on Aβ induced membrane disruption. Acs Chemical Neuroscience. 2: 588-599. PMID 22125665 DOI: 10.1021/Cn2000475  0.42
2011 Holtzman DM. CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiology of Aging. 32: S4-9. PMID 22078172 DOI: 10.1016/J.Neurobiolaging.2011.09.003  0.441
2011 Verghese PB, Sasaki Y, Yang D, Stewart F, Sabar F, Finn MB, Wroge CM, Mennerick S, Neil JJ, Milbrandt J, Holtzman DM. Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell death. Proceedings of the National Academy of Sciences of the United States of America. 108: 19054-9. PMID 22058226 DOI: 10.1073/Pnas.1107325108  0.724
2011 Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ. Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 15861-9. PMID 22049429 DOI: 10.1523/Jneurosci.3272-11.2011  0.723
2011 Xiong C, Roe CM, Buckles V, Fagan A, Holtzman D, Balota D, Duchek J, Storandt M, Mintun M, Grant E, Snyder AZ, Head D, Benzinger TL, Mettenburg J, Csernansky J, et al. Role of family history for Alzheimer biomarker abnormalities in the adult children study. Archives of Neurology. 68: 1313-9. PMID 21987546 DOI: 10.1001/Archneurol.2011.208  0.417
2011 Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow EM, Diamond MI, Lee VM, Holtzman DM. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 13110-7. PMID 21917794 DOI: 10.1523/Jneurosci.2569-11.2011  0.693
2011 Roe CM, Fagan AM, Grant EA, Marcus DS, Benzinger TL, Mintun MA, Holtzman DM, Morris JC. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. Archives of Neurology. 68: 1145-51. PMID 21911695 DOI: 10.1001/archneurol.2011.192  0.343
2011 Cruchaga C, Nowotny P, Kauwe JS, Ridge PG, Mayo K, Bertelsen S, Hinrichs A, Fagan AM, Holtzman DM, Morris JC, Goate AM. Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Archives of Neurology. 68: 1013-9. PMID 21825236 DOI: 10.1001/Archneurol.2011.155  0.39
2011 Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Annals of Neurology. 70: 274-85. PMID 21823155 DOI: 10.1002/Ana.22448  0.446
2011 Verges DK, Restivo JL, Goebel WD, Holtzman DM, Cirrito JR. Opposing synaptic regulation of amyloid-β metabolism by NMDA receptors in vivo. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 11328-37. PMID 21813692 DOI: 10.1523/Jneurosci.0607-11.2011  0.646
2011 Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, ... ... Holtzman DM, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: 386-395.e6. PMID 21784349 DOI: 10.1016/J.Jalz.2011.05.2243  0.411
2011 Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Science Translational Medicine. 3: 89ra57. PMID 21715678 DOI: 10.1126/Scitranslmed.3002156  0.826
2011 Tran HT, LaFerla FM, Holtzman DM, Brody DL. Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 9513-25. PMID 21715616 DOI: 10.1523/Jneurosci.0858-11.2011  0.489
2011 Hata S, Fujishige S, Araki Y, Taniguchi M, Urakami K, Peskind E, Akatsu H, Araseki M, Yamamoto K, Martins RN, Maeda M, Nishimura M, Levey A, Chung KA, Montine T, ... ... Holtzman DM, et al. Alternative processing of γ-secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: evidence for γ-secretase dysfunction. Annals of Neurology. 69: 1026-31. PMID 21681798 DOI: 10.1002/Ana.22343  0.592
2011 Lim MM, Xu J, Holtzman DM, Mach RH. Sleep deprivation differentially affects dopamine receptor subtypes in mouse striatum. Neuroreport. 22: 489-93. PMID 21642879 DOI: 10.1097/Wnr.0B013E32834846A0  0.566
2011 Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JÅ, Holtzman DM, Heneka MT. Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 7049-59. PMID 21562267 DOI: 10.1523/Jneurosci.6546-10.2011  0.793
2011 Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Archives of Neurology. 68: 1137-44. PMID 21555603 DOI: 10.1001/Archneurol.2011.105  0.495
2011 Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nature Neuroscience. 14: 750-6. PMID 21532579 DOI: 10.1038/Nn.2801  0.834
2011 Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. Plos One. 6: e18850. PMID 21526197 DOI: 10.1371/Journal.Pone.0018850  0.813
2011 Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Science Translational Medicine. 3: 77sr1. PMID 21471435 DOI: 10.1126/Scitranslmed.3002369  0.42
2011 Lodygensky GA, West T, Moravec MD, Back SA, Dikranian K, Holtzman DM, Neil JJ. Diffusion characteristics associated with neuronal injury and glial activation following hypoxia-ischemia in the immature brain. Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 66: 839-45. PMID 21394776 DOI: 10.1002/Mrm.22869  0.546
2011 Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. The Lancet. Neurology. 10: 241-52. PMID 21349439 DOI: 10.1016/S1474-4422(10)70325-2  0.834
2011 Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, Latu W, Su'a M, Fagan AM, Holtzman DM, Morris JC, Goate AM. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. Plos One. 6: e15918. PMID 21347408 DOI: 10.1371/Journal.Pone.0015918  0.421
2011 Pasic MD, Diamandis EP, McLaurin J, Holtzman DM, Schmitt-Ulms G, Quirion R. Alzheimer disease: advances in pathogenesis, diagnosis, and therapy. Clinical Chemistry. 57: 664-9. PMID 21310870 DOI: 10.1373/Clinchem.2011.161828  0.457
2011 Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. Plos One. 6: e16032. PMID 21264269 DOI: 10.1371/Journal.Pone.0016032  0.824
2011 Roe CM, Fagan AM, Williams MM, Ghoshal N, Aeschleman M, Grant EA, Marcus DS, Mintun MA, Holtzman DM, Morris JC. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology. 76: 501-10. PMID 21228296 DOI: 10.1212/Wnl.0B013E31820Af900  0.329
2011 Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, Ghosh AK, Tang J. Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 25: 775-84. PMID 21059748 DOI: 10.1096/Fj.10-167213  0.694
2011 Elbert DL, Patterson BW, Ercole L, Ovod V, Kasten T, Mawuenyega K, Yarasheski K, Morris JC, Benzinger T, Holtzman DM, Bateman RJ. Reply to: Fractional synthesis and clearance rates for amyloid β Nature Medicine. 17: 1179-1180. DOI: 10.1038/Nm.2496  0.529
2011 Kauwe J, Cruchaga C, McKean D, Bailey M, Patty D, Mayo K, Bertelsen S, Hinrichs A, Disease Genetics Consortium TA, Disease Neuroimaging Initiative TA, Fagan A, Holtzman D, Goate A. P4-453: Genome-wide association analysis using cerebrospinal fluid Abeta42 levels as an endophenotype for Alzheimer's disease Alzheimer's & Dementia. 7: e69-e70. DOI: 10.1016/J.Jalz.2011.09.148  0.409
2011 Bailey M, Kauwe J, Cruchaga C, McKean D, Mayo K, Bertelsen S, Hinrichs T, Fagan A, Holtzman D, Goate A. P2-018: Association study of recently reported AD risk variants with cerebrospinal fluid AD biomarker levels Alzheimer's & Dementia. 7: S313-S313. DOI: 10.1016/J.Jalz.2011.05.908  0.415
2011 Head D, Bugg J, Goate A, Fagan A, Mintun M, Benzinger T, Holtzman D, Morris J. P1-377: Interactive effects of a sedentary lifestyle and the APOE e4 allele on amyloid deposition Alzheimer's & Dementia. 7: S233-S233. DOI: 10.1016/J.Jalz.2011.05.658  0.367
2011 Cruchaga C, Nowotny P, Kauwe J, Mayo K, Bertelsen S, Hinrichs T, Fagan A, Holtzman D, Morris J, Goate A. P1-224: APOE Genotype is Associated with Cerebrospinal Fluid and Plasma APOE Levels But Not with APOE Expression Levels Alzheimer's & Dementia. 7: S182-S183. DOI: 10.1016/J.Jalz.2011.05.504  0.33
2011 Cruchaga C, Kauwe J, Mayo K, Bertelsen S, Hinrichs T, Peskind E, Li G, Leverenz J, Galasko D, Fagan A, Holtzman D, Goate A. Genome-Wide Association Analyses Using Cerebrospinal Fluid Tau and Phospho-Tau Levels As An Endophenotype for Alzheimer’s Disease Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.503  0.369
2011 Benitez B, Cruchaga C, Kauwe J, Mayo K, Bertelsen S, Hinrichs A, Fagan A, Holtzman D, Goate A. Rare Genetic Variants in APP, PSEN1, PSEN2, GRN, APOE and MAPT Associated with CSF Aß and tau/ptau181 Levels in Patients with Late-Onset Alzheimer’s Disease Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.492  0.403
2011 Snider BJ, Holtzman D, Fagan A, Ghoshal N, Morris J. P1-114: Diagnostic utility of CSF biomarkers in an Alzheimer's clinic Alzheimer's & Dementia. 7: S146-S146. DOI: 10.1016/J.Jalz.2011.05.393  0.365
2011 Hu WT, Holtzman D, Clark C, Grossman M, Karlawish J, Fagan A, Lee V, Swenson F, Craig-Schapiro R, Perrin RJ, Soares H, Trojanowski J, Xiong C, Morris J, Shaw L, et al. P1-089: Plasma multianalyte profiling of mild cognitive impairment and Alzheimer's disease in two academic centers and the Alzheimer's Disease Neuroimaging Initiative Alzheimer's & Dementia. 7: S138-S138. DOI: 10.1016/J.Jalz.2011.05.368  0.811
2011 Holtzman D, Hyman B, Lee V, Spires-Jones T, Koffie R, Hashimoto T, Joyner D, Hou S, Kopeikina K, Frosch M. O1-05-01: APOE4 plays a role in Abeta-mediated synapse loss in Alzheimer's disease Alzheimer's & Dementia. 7: S103-S104. DOI: 10.1016/J.Jalz.2011.05.256  0.411
2011 Goate A, Holtzman D, Morris J, Cruchaga C, Nowotny P, Kauwe J, Fagan A, Mayo K, Bertelsen S, Hinrichs T. Association and expression analyses with SNPs in TOMM40 in Alzheimer's disease Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.227  0.363
2011 Fagan A, Xiong C, Bateman R, Goate A, Holtzman D, Ghetti B, Martins R, Masters C, Mayeux R, Ringman J, Rossor M, Salloway S, Schofield P, Sperling R, Morris J. Plasma and Cerebrospinal Fluid Markers in the DIAN Study of Autosomal-Dominant Alzheimer’s Disease Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.1960  0.517
2011 Castellano J, Verghese P, Stewart F, DeMattos R, Holtzman D. P2-221: Synthetic human apoE particles differentially regulate brain interstitial amyloid-beta levels Alzheimer's & Dementia. 7: S383-S383. DOI: 10.1016/J.Jalz.2011.05.1103  0.796
2011 Basak JM, Holtzman DM. APP-based transgenic models: The PDAPP model Neuromethods. 48: 371-385. DOI: 10.1007/978-1-60761-898-0_18  0.742
2010 Kim J, Holtzman DM. Medicine. Prion-like behavior of amyloid-beta. Science (New York, N.Y.). 330: 918-9. PMID 21071652 DOI: 10.1126/Science.1198314  0.674
2010 Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, ... ... Holtzman DM, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biological Psychiatry. 68: 903-12. PMID 21035623 DOI: 10.1016/J.Biopsych.2010.08.025  0.839
2010 Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MM, Williams J, Lovestone S, Peskind ER, Li G, ... ... Holtzman DM, et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. Plos Genetics. 6: e1001101. PMID 20862329 DOI: 10.1371/Journal.Pgen.1001101  0.435
2010 Galvin JE, Fagan AM, Holtzman DM, Mintun MA, Morris JC. Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain : a Journal of Neurology. 133: 3290-300. PMID 20823087 DOI: 10.1093/Brain/Awq204  0.45
2010 Liang KY, Mintun MA, Fagan AM, Goate AM, Bugg JM, Holtzman DM, Morris JC, Head D. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Annals of Neurology. 68: 311-8. PMID 20818789 DOI: 10.1002/Ana.22096  0.378
2010 Schwetye KE, Cirrito JR, Esparza TJ, Mac Donald CL, Holtzman DM, Brody DL. Traumatic brain injury reduces soluble extracellular amyloid-β in mice: a methodologically novel combined microdialysis-controlled cortical impact study. Neurobiology of Disease. 40: 555-64. PMID 20682338 DOI: 10.1016/J.Nbd.2010.06.018  0.647
2010 Satoh A, Brace CS, Ben-Josef G, West T, Wozniak DF, Holtzman DM, Herzog ED, Imai S. SIRT1 promotes the central adaptive response to diet restriction through activation of the dorsomedial and lateral nuclei of the hypothalamus. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 10220-32. PMID 20668205 DOI: 10.1523/Jneurosci.1385-10.2010  0.742
2010 Kauwe JS, Cruchaga C, Bertelsen S, Mayo K, Latu W, Nowotny P, Hinrichs AL, Fagan AM, Holtzman DM, Goate AM. Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. Journal of Alzheimer's Disease : Jad. 21: 833-42. PMID 20634593 DOI: 10.3233/Jad-2010-091711  0.393
2010 Ances BM, Christensen JJ, Teshome M, Taylor J, Xiong C, Aldea P, Fagan AM, Holtzman DM, Morris JC, Mintun MA, Clifford DB. Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology. 75: 111-5. PMID 20534887 DOI: 10.1212/Wnl.0B013E3181E7B66E  0.358
2010 Tarawneh R, Holtzman DM. Biomarkers in translational research of Alzheimer's disease. Neuropharmacology. 59: 310-22. PMID 20394760 DOI: 10.1016/J.Neuropharm.2010.04.006  0.514
2010 Dietrich HH, Xiang C, Han BH, Zipfel GJ, Holtzman DM. Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Molecular Neurodegeneration. 5: 15. PMID 20388225 DOI: 10.1186/1750-1326-5-15  0.406
2010 Goate A, Holtzman DM. Biomarkers will revolutionize the way we diagnose and treat Alzheimer's disease. Biomarkers in Medicine. 4: 1-2. PMID 20387300 DOI: 10.2217/Bmm.10.3  0.408
2010 Fagan AM, Holtzman DM. Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomarkers in Medicine. 4: 51-63. PMID 20361010 DOI: 10.2217/Bmm.09.83  0.41
2010 Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Annals of Neurology. 67: 122-31. PMID 20186853 DOI: 10.1002/Ana.21843  0.447
2010 Zeng C, Pan F, Jones LA, Lim MM, Griffin EA, Sheline YI, Mintun MA, Holtzman DM, Mach RH. Evaluation of 5-ethynyl-2'-deoxyuridine staining as a sensitive and reliable method for studying cell proliferation in the adult nervous system. Brain Research. 1319: 21-32. PMID 20064490 DOI: 10.1016/J.Brainres.2009.12.092  0.56
2010 Zeng LH, Bero AW, Zhang B, Holtzman DM, Wong M. Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex. Neurobiology of Disease. 37: 764-71. PMID 20045054 DOI: 10.1016/J.Nbd.2009.12.020  0.776
2010 Lodygensky GA, West T, Stump M, Holtzman DM, Inder TE, Neil JJ. In vivo MRI analysis of an inflammatory injury in the developing brain. Brain, Behavior, and Immunity. 24: 759-67. PMID 19945527 DOI: 10.1016/J.Bbi.2009.11.005  0.536
2010 Hinrichs AL, Mintun MA, Head D, Fagan AM, Holtzman DM, Morris JC, Goate AM. Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease. Biological Psychiatry. 67: 581-3. PMID 19892322 DOI: 10.1016/J.Biopsych.2009.09.012  0.43
2010 Cheng H, Zhou Y, Holtzman DM, Han X. Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease. Neurobiology of Aging. 31: 1188-96. PMID 18762354 DOI: 10.1016/J.Neurobiolaging.2008.07.020  0.512
2010 Snider BJ, Pizzie RG, Roe CM, Grant EA, Fagan AM, Holtzman DM, Morris JC. P4-149: Accuracy of Clinical Diagnosis of Dementia of the Alzheimer Type: Impact of Longitudinal Follow-up and Inclusion of CSF Biomarkers Alzheimer's & Dementia. 6: e67-e67. DOI: 10.1016/J.Jalz.2010.08.208  0.369
2010 Tarawneh R, Ohlendorf MF, Macy EM, McQuillan J, Head D, Cairns NJ, Fagan AM, Mintun MA, Ladenson JH, Lee J, Morris JC, Holtzman DM. P4-060: The Novel Neuronal Injury Marker, Visinin-like Protein-1 (VILIP-1), as a Diagnostic and Prognostic Marker in Alzheimer's Disease Alzheimer's & Dementia. 6: e38-e39. DOI: 10.1016/J.Jalz.2010.08.120  0.351
2010 Brautigam H, Klingstedt T, Prokop S, Holtzman DM, Heppner FL, Haroutunian V, Dickstein DL, Hof PR, Nilsson PR, Gandy S. O4-08-06: New Conformation-Sensing Imaging Compounds Distinguish Protein Deposits In Apoe ε3/ε3 Alzheimer's Patients From that in Apoe ε4/ε4 Alzheimer's Patients Alzheimer's & Dementia. 6: e19-e20. DOI: 10.1016/J.Jalz.2010.08.059  0.385
2010 Karch CM, Jeng A, Cruchaga C, Kauwe JS, Renaud N, Fagan AM, Holtzman DM, Morris JC, Goate AM. P1-090: The effects of Alzheimer's disease associated transferrin variants on APP metabolism Alzheimer's & Dementia. 6: S200-S200. DOI: 10.1016/J.Jalz.2010.05.638  0.406
2010 Cruchaga C, Kauwe JS, Mayo K, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MJ, Williams J, Lovestone S, Morris JC, Fagan AM, Holtzman DM, et al. SNPs associated with CSF tau levels modify rate of progression in Alzheimer's disease Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.612  0.314
2010 Bero AW, Stewart FR, Parsadanian M, Holtzman DM. O4-02-06: Regional cerebral glucose metabolism is associated with interstitial fluid Aβ concentration and plaque deposition in Tg2576 mice Alzheimer's & Dementia. 6: S154-S154. DOI: 10.1016/J.Jalz.2010.05.478  0.806
2010 Castellano JM, Stewart FR, May PC, DeMattos RB, Paul SM, Holtzman DM. O4-02-03: Soluble Aβ clearance from the brain interstitial fluid of PDAPP mice is human apoE isoform-dependent Alzheimer's & Dementia. 6: S153-S153. DOI: 10.1016/J.Jalz.2010.05.475  0.658
2010 Kauwe JSK, Cruchaga C, Bertelsen S, Mayo K, Latu W, Nowotny P, Hinrichs AL, Fagan AM, Holtzman DM, Goate AM. Validating predicted biological effects of Alzheimer's disease associated SNPs using cerebrospinal fluid biomarker levels Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.348  0.369
2010 Galvin JE, Fagan AM, Holtzman DM, Storandt M, Mintun MA, Morris JC. P3-223: Correlation of the AD8, an informant-based dementia screening tool, with amyloid imaging and CSF biomarkers of Alzheimer disease Alzheimer's & Dementia. 6: S516-S516. DOI: 10.1016/j.jalz.2010.05.1722  0.329
2010 Craig-Schapiro R, Perrin RJ, Roe CM, Grant EA, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, ... ... Holtzman DM, et al. P3-190: A novel diagnostic and prognostic fluid biomarker for early Alzheimer's disease: YKL-40 Alzheimer's & Dementia. 6: S506-S506. DOI: 10.1016/J.Jalz.2010.05.1688  0.808
2010 Perrin RJ, Craig-Schapiro R, Malone JP, Roe CM, Grant EA, Shah AR, Gilmore P, Davis AE, Peskind ER, Li G, Galasko DR, Quinn JF, Kaye JA, Clark CM, Morris JC, ... Holtzman DM, et al. P3-172: Identification and validation of novel cerebrospinal fluid protein biomarkers for early Alzheimer's disease using proteomics and ELISA: a multi-institutional collaborative study Alzheimer's & Dementia. 6: S500-S500. DOI: 10.1016/J.Jalz.2010.05.1670  0.779
2010 Hata S, Urakami K, Fagan A, Peskind E, Akatsu H, Maeda M, Levey A, Chung KA, Montine T, Leverenz J, Goate A, Bateman R, Holtzman DM, Gandy S, Suzuki T. P3-171: Gamma-secretase dysfunction in sporadic Alzhemer's disease suggested by p3-Alc peptide, metabolic product of Alcadein Alzheimer's & Dementia. 6: S499-S500. DOI: 10.1016/J.Jalz.2010.05.1669  0.519
2010 Galvin JE, Fagan AM, Holtzman DM, Storandt M, Mintun MA, Morris JC. IC-P-007: Correlation of the AD8: an Informant-Based Dementia Screening Tool with Amyloid Imaging and CSF Biomarkers of Alzheimer Disease Alzheimer's & Dementia. 6: S8-S9. DOI: 10.1016/J.Jalz.2010.05.022  0.409
2010 Holtzman D. Diagnostic markers: Detection of preclinical pathology, prognostic capabilities, and dynamic metabolism of Abeta and tau Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.003  0.361
2009 Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. Embo Molecular Medicine. 1: 371-80. PMID 20049742 DOI: 10.1002/Emmm.200900048  0.512
2009 Holtzman DM. A surrogate marker for Abeta42 production in the CNS. Embo Molecular Medicine. 1: 195-7. PMID 20049720 DOI: 10.1002/Emmm.200900030  0.497
2009 Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL, Westaway D, Fraser P, Hyslop PS, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM, Gandy S. Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Molecular Neurodegeneration. 4: 51. PMID 20017949 DOI: 10.1186/1750-1326-4-51  0.702
2009 Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Archives of Neurology. 66: 1557-62. PMID 20008664 DOI: 10.1001/Archneurol.2009.279  0.449
2009 Holtzman DM. Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realization. Archives of Neurology. 66: 1552-3. PMID 20008662 DOI: 10.1001/Archneurol.2009.270  0.463
2009 Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Archives of Neurology. 66: 1469-75. PMID 20008650 DOI: 10.1001/Archneurol.2009.269  0.4
2009 Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 64: 632-44. PMID 20005821 DOI: 10.1016/J.Neuron.2009.11.013  0.833
2009 Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, Kauwe JS. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology. 73: 1982-7. PMID 19907013 DOI: 10.1212/Wnl.0B013E3181C5B445  0.376
2009 Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 461: 916-22. PMID 19829371 DOI: 10.1038/Nature08538  0.69
2009 Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science (New York, N.Y.). 326: 1005-7. PMID 19779148 DOI: 10.1126/Science.1180962  0.809
2009 Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 10706-14. PMID 19710322 DOI: 10.1523/Jneurosci.2637-09.2009  0.829
2009 Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 63: 287-303. PMID 19679070 DOI: 10.1016/J.Neuron.2009.06.026  0.84
2009 Aslund A, Sigurdson CJ, Klingstedt T, Grathwohl S, Bolmont T, Dickstein DL, Glimsdal E, Prokop S, Lindgren M, Konradsson P, Holtzman DM, Hof PR, Heppner FL, Gandy S, Jucker M, et al. Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. Acs Chemical Biology. 4: 673-84. PMID 19624097 DOI: 10.1021/Cb900112V  0.442
2009 Cao C, Cirrito JR, Lin X, Wang L, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. Journal of Alzheimer's Disease : Jad. 17: 681-97. PMID 19581723 DOI: 10.3233/Jad-2009-1071  0.711
2009 Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 106: 12145-50. PMID 19581601 DOI: 10.1073/Pnas.0904866106  0.584
2009 West T, Stump M, Lodygensky G, Neil JJ, Deshmukh M, Holtzman DM. Lack of X-linked inhibitor of apoptosis protein leads to increased apoptosis and tissue loss following neonatal brain injury. Asn Neuro. 1. PMID 19570023 DOI: 10.1042/An20090005  0.563
2009 Yuede CM, Zimmerman SD, Dong H, Kling MJ, Bero AW, Holtzman DM, Timson BF, Csernansky JG. Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer's disease. Neurobiology of Disease. 35: 426-32. PMID 19524672 DOI: 10.1016/J.Nbd.2009.06.002  0.816
2009 Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Archives of Neurology. 66: 638-45. PMID 19433664 DOI: 10.1001/Archneurol.2009.55  0.449
2009 Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Annals of Neurology. 66: 48-54. PMID 19360898 DOI: 10.1002/Ana.21623  0.595
2009 Tarawneh R, Holtzman DM. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. Cns & Neurological Disorders Drug Targets. 8: 144-59. PMID 19355934 DOI: 10.2174/187152709787847324  0.461
2009 Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 4252-62. PMID 19339619 DOI: 10.1523/Jneurosci.5572-08.2009  0.424
2009 Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Annals of Neurology. 65: 176-83. PMID 19260027 DOI: 10.1002/Ana.21559  0.508
2009 Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer's disease. Neurobiology of Disease. 35: 128-40. PMID 19010417 DOI: 10.1016/J.Nbd.2008.10.003  0.781
2009 Kauwe JS, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, Goate AM. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics. 10: 13-7. PMID 18813964 DOI: 10.1007/S10048-008-0150-4  0.436
2009 Gandy S, Cirrito J, Steele J, Kim SH, Thinakaran G, Westaway D, Fraser P, St George Hyslop P, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM. S4-04-06: Dimebon®: A Clinically Promising Drug for Alzheimer's Disease, Regulates Amyloid-Beta Metabolism in Cultured Cells, In Isolated Nerve Terminals, and In the Interstitial Fluid of the Living Rodent Brain Alzheimer's & Dementia. 5: e5-e5. DOI: 10.1016/J.Jalz.2009.07.133  0.668
2009 Kraft AW, Hu X, Yan P, Xiao Q, Holmes BB, Wilhelmsson U, Cirrito JR, Holtzman DM, Pekny M, Lee J. Activated astrocytes suppress amyloid plaque pathogenesis in APP/PS1 mice Alzheimers & Dementia. 5: 154. DOI: 10.1016/J.Jalz.2009.05.532  0.688
2009 Brody DL, Magnoni S, Esparza TJ, MacDonald C, Schwetye K, Spinner M, Stocchetti N, Holtzman D, Zipfel G. O2-06-01: Amyloid-beta dynamics in the injured human brain Alzheimer's & Dementia. 5: P115-P115. DOI: 10.1016/J.Jalz.2009.05.361  0.345
2009 Hata S, Maeda M, Nishimura M, Levey A, Chung KA, Montine T, Fagan A, Goate A, Bateman R, Holtzman DM, Nakaya T, Gandy S, Suzuki T. P2-190: p3-Alc peptides produced by covariant processing of Alcadein and APP implicate γ-secretase dysfunction in sporadic Alzheimer's disease Alzheimer's & Dementia. 5: P316-P317. DOI: 10.1016/J.Jalz.2009.04.502  0.571
2008 Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT, Bacskai BJ, Holtzman DM. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 14156-64. PMID 19109498 DOI: 10.1523/Jneurosci.4147-08.2008  0.456
2008 Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, Cirrito JR, Milner E, Holtzman DM, Zipfel GJ. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 13542-50. PMID 19074028 DOI: 10.1523/Jneurosci.4686-08.2008  0.702
2008 Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. The Journal of Clinical Investigation. 118: 4002-13. PMID 19033669 DOI: 10.1172/Jci36663  0.506
2008 Yamada K, Hashimoto T, Yabuki C, Nagae Y, Tachikawa M, Strickland DK, Liu Q, Bu G, Basak JM, Holtzman DM, Ohtsuki S, Terasaki T, Iwatsubo T. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. The Journal of Biological Chemistry. 283: 34554-62. PMID 18940800 DOI: 10.1074/Jbc.M801487200  0.775
2008 Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science (New York, N.Y.). 321: 1221-4. PMID 18755980 DOI: 10.1126/Science.1161591  0.427
2008 Maysinger D, Holmes M, Han X, Epand RM, Pertens E, Foerster A, Barlas C, Holtzman DM, Diamond J. Ceramide is responsible for the failure of compensatory nerve sprouting in apolipoprotein E knock-out mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 7891-9. PMID 18667621 DOI: 10.1523/Jneurosci.1461-08.2008  0.35
2008 Holtzman DM. Alzheimer's disease: Moving towards a vaccine. Nature. 454: 418-20. PMID 18650906 DOI: 10.1038/454418A  0.425
2008 Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron. 58: 681-93. PMID 18549781 DOI: 10.1016/J.Neuron.2008.04.010  0.475
2008 Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, Galimberti D, Scarpini E, Morris JC, Fagan AM, Holtzman DM, Goate AM. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proceedings of the National Academy of Sciences of the United States of America. 105: 8050-4. PMID 18541914 DOI: 10.1073/Pnas.0801227105  0.472
2008 Wendland MF, Faustino J, West T, Manabat C, Holtzman DM, Vexler ZS. Early diffusion-weighted MRI as a predictor of caspase-3 activation after hypoxic-ischemic insult in neonatal rodents. Stroke; a Journal of Cerebral Circulation. 39: 1862-8. PMID 18420950 DOI: 10.1161/Strokeaha.107.506352  0.522
2008 Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 58: 42-51. PMID 18400162 DOI: 10.1016/J.Neuron.2008.02.003  0.685
2008 Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annual Review of Neuroscience. 31: 175-93. PMID 18352830 DOI: 10.1146/Annurev.Neuro.31.060407.125529  0.436
2008 Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 451: 720-4. PMID 18256671 DOI: 10.1038/Nature06616  0.514
2008 Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. The Journal of Clinical Investigation. 118: 671-82. PMID 18202749 DOI: 10.1172/Jci33622  0.709
2008 Wippold FJ, Cairns N, Vo K, Holtzman DM, Morris JC. Neuropathology for the neuroradiologist: plaques and tangles. Ajnr. American Journal of Neuroradiology. 29: 18-22. PMID 17925367 DOI: 10.3174/Ajnr.A0781  0.463
2008 Fagan AM, Mintun MA, Shah AR, Mach RH, Morris JC, Holtzman DM. O3-02-02: Update on the relationship between in vivo amyloid imaging with C-PIB and CSF Aβ42 Alzheimer's & Dementia. 4: T160-T160. DOI: 10.1016/J.Jalz.2008.05.415  0.372
2008 Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, Galimberti D, Scarpini E, Shah AR, Morris JC, Fagan AM, Holtzman DM, Goate AM. O2-06-06: SNPS in MAPT are associated with cerebrospinal fluid Tau levels, MAPT mRNA levels, and age at onset of late-onset Alzheimer's disease Alzheimer's & Dementia. 4: T145-T145. DOI: 10.1016/J.Jalz.2008.05.354  0.38
2008 Goate AM, Kauwe JS, Mayo K, Bertelsen S, Shah AR, Morris JC, Fagan AM, Holtzman DM. O2-06-03: Late-onset Alzheimer's Disease-associated SNPS in TOMM40 and APOE have different effects on cerebrospinal fluid amyloid-beta levels Alzheimer's & Dementia. 4: T144-T144. DOI: 10.1016/J.Jalz.2008.05.351  0.43
2008 Hinrichs AL, Mintun M, Head D, Fagan AM, Holtzman DM, Morris JC, Goate A. IC-01-01: Cortical binding of Pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease Alzheimer's & Dementia. 4: T2-T2. DOI: 10.1016/J.Jalz.2008.05.2487  0.305
2008 Cirrito JR, Stewart FR, Mennerick S, Holtzman DM. P4-268: APP endocytosis is required for synaptic-dependent release of amyloid-beta in vivo Alzheimer's & Dementia. 4: T750-T750. DOI: 10.1016/J.Jalz.2008.05.2337  0.647
2008 Lee J, Bero A, Cirrito JR, Hu X, Gonzales E, Perez R, Xiao Q, Holtzman DM, Yan P. O1-03-05: Dynamics of compact plaque growth in APP/PS1 mice Alzheimer's & Dementia. 4: T113-T113. DOI: 10.1016/J.Jalz.2008.05.233  0.787
2008 Kang J, Cirrito J, Lee J, Fujiki N, Nishino S, Holtzman D. P4-081: Diurnal fluctuation of amyloid-β in the brain interstitial fluid of young Tg2576 mice Alzheimer's & Dementia. 4: T692-T692. DOI: 10.1016/J.Jalz.2008.05.2146  0.664
2008 Kim J, Basak J, Wildsmith KR, Jiang H, Mawuenyega KG, Bateman RJ, Parsadanian M, Holtzman DM. P3-296: Assessment of human apolipoprotein E and Aβ clearance rate in vivo through use of stable isotope-labeling and tandem mass spectrometry Alzheimer's & Dementia. 4: T609-T609. DOI: 10.1016/J.Jalz.2008.05.1864  0.788
2008 Kauwe JS, Mayo K, Bertelsen S, Shah AR, Morris JC, Fagan AM, Holtzman DM, Goate AM. P3-232: SNPs in SOAT1, TFAM, and CNDP1 are associated with cerebrospinal fluid amyloid-beta levels Alzheimer's & Dementia. 4: T588-T589. DOI: 10.1016/J.Jalz.2008.05.1799  0.331
2008 Cruchaga C, Kauwe J, Mayo K, Bertelsen S, Nowotny P, Shah AR, Fagan AM, Holtzman DM, Morris JC, Goate A. P3-214: Cerebrospinal fluid tau levels, an endophenotype for genetic studies of Alzheimer's disease Alzheimer's & Dementia. 4: T583-T583. DOI: 10.1016/J.Jalz.2008.05.1781  0.416
2008 Wang L, Fagan A, Holtzman D, Miller JP, Morris JC, Csernansky JG. P3-102: Correlating hippocampal structure and CSF proteins in early dementia of the Alzheimer type Alzheimer's & Dementia. 4: T548-T549. DOI: 10.1016/J.Jalz.2008.05.1667  0.375
2008 Snider BJ, Fagan AM, Roe CM, Shah AR, Grant EA, Morris JC, Holtzman DM. P3-095: Levels of CSF biomarkers predict rate of cognitive decline in individuals with very mild dementia of the Alzheimer's type Alzheimer's & Dementia. 4: T546-T546. DOI: 10.1016/J.Jalz.2008.05.1659  0.36
2008 Perrin RJ, Malone JP, Shah AR, Craig-Schapiro R, Gilmore P, Davis AE, Peskind ER, Li G, Galasko DR, Quinn JF, Kaye JA, Clark CM, Morris JC, Holtzman DM, Townsend RR, et al. P3-088: Identification of potential biomarkers for Alzheimer's disease in cerebrospinal fluid using two-dimensional difference gel electrophoresis and tandem mass spectrometry: A multi-institutional collaborative study Alzheimer's & Dementia. 4: T543-T543. DOI: 10.1016/J.Jalz.2008.05.1652  0.8
2008 Craig-Schapiro R, Davis AE, LeDuc RD, Shah AR, Holtzman DM, Townsend RR, Fagan AM. P3-065: Development of a solid phase extraction protocol for extracting peptides from cerebrospinal fluid in conjunction with tandem mass spectrometry to identify novel biomarkers for Alzheimer's disease Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.1629  0.745
2008 Britschgi M, Olin CE, Johns H, Takeda-Uchimura Y, Rufibach K, Tomooka B, Robinson WH, Rajadas J, Clark CM, Fagan AM, Galasko DG, Holtzman DM, Jutel M, Leszek J, Li G, et al. P2-294: Microarray profiling reveals autoantibody reactivities against abnormal amyloid peptide conformations decline with age and in Alzheimer's disease Alzheimer's & Dementia. 4: T458-T459. DOI: 10.1016/J.Jalz.2008.05.1370  0.617
2007 Hu Y, Hosseini A, Kauwe JS, Gross J, Cairns NJ, Goate AM, Fagan AM, Townsend RR, Holtzman DM. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics. Clinical Applications. 1: 1373-84. PMID 21136637 DOI: 10.1002/Prca.200600999  0.445
2007 West T, Atzeva M, Holtzman DM. Pomegranate polyphenols and resveratrol protect the neonatal brain against hypoxic-ischemic injury. Developmental Neuroscience. 29: 363-72. PMID 17762204 DOI: 10.1159/000105477  0.53
2007 Zeng LH, Ouyang Y, Gazit V, Cirrito JR, Jansen LA, Ess KC, Yamada KA, Wozniak DF, Holtzman DM, Gutmann DH, Wong M. Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiology of Disease. 28: 184-96. PMID 17714952 DOI: 10.1016/J.Nbd.2007.07.015  0.696
2007 Farris W, Schütz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. The American Journal of Pathology. 171: 241-51. PMID 17591969 DOI: 10.2353/Ajpath.2007.070105  0.714
2007 Gelfanova V, Higgs RE, Dean RA, Holtzman DM, Farlow MR, Siemers ER, Boodhoo A, Qian YW, He X, Jin Z, Fisher DL, Cox KL, Hale JE. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Briefings in Functional Genomics & Proteomics. 6: 149-58. PMID 17584762 DOI: 10.1093/Bfgp/Elm010  0.407
2007 Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proceedings of the National Academy of Sciences of the United States of America. 104: 10673-8. PMID 17551018 DOI: 10.1073/Pnas.0700148104  0.665
2007 Wahrle SE, Shah AR, Fagan AM, Smemo S, Kauwe JS, Grupe A, Hinrichs A, Mayo K, Jiang H, Thal LJ, Goate AM, Holtzman DM. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Molecular Neurodegeneration. 2: 7. PMID 17430597 DOI: 10.1186/1750-1326-2-7  0.431
2007 Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE. Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. Journal of the American Society For Mass Spectrometry. 18: 997-1006. PMID 17383190 DOI: 10.1016/J.Jasms.2007.02.009  0.558
2007 Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, Holtzman DM, Morris JC, Goate AM. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Annals of Neurology. 61: 446-53. PMID 17366635 DOI: 10.1002/Ana.21099  0.493
2007 Holtzman DM. Pittsburgh compound B retention and verification of amyloid deposition. Archives of Neurology. 64: 315-6. PMID 17353372 DOI: 10.1001/Archneur.64.3.315  0.317
2007 Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 68: 666-9. PMID 17325273 DOI: 10.1212/01.Wnl.0000256043.50901.E3  0.577
2007 Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Archives of Neurology. 64: 343-9. PMID 17210801 DOI: 10.1001/Archneur.64.3.Noc60123  0.496
2007 Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 27: 909-18. PMID 17077814 DOI: 10.1038/Sj.Jcbfm.9600419  0.451
2007 Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Medication Use as a Confounding Factor in the Use of the Cerebrospinal Fluid tau/β-Amyloid42 Ratio—Reply Archives of Neurology. 64: 1357. DOI: 10.1001/Archneur.64.9.1357-B  0.341
2006 Oe T, Ackermann BL, Inoue K, Berna MJ, Garner CO, Gelfanova V, Dean RA, Siemers ER, Holtzman DM, Farlow MR, Blair IA. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 20: 3723-35. PMID 17117458 DOI: 10.1002/Rcm.2787  0.401
2006 Yin KJ, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X, Bateman R, Song H, Hsu FF, Turk J, Xu J, Hsu CY, Mills JC, Holtzman DM, Lee JM. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 10939-48. PMID 17065436 DOI: 10.1523/Jneurosci.2085-06.2006  0.752
2006 Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtzman DM, Bu G. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. The Journal of Biological Chemistry. 281: 36180-6. PMID 17012232 DOI: 10.1074/Jbc.M604436200  0.482
2006 Hartman RE, Shah A, Fagan AM, Schwetye KE, Parsadanian M, Schulman RN, Finn MB, Holtzman DM. Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. Neurobiology of Disease. 24: 506-15. PMID 17010630 DOI: 10.1016/J.Nbd.2006.08.006  0.676
2006 Schlief ML, West T, Craig AM, Holtzman DM, Gitlin JD. Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity. Proceedings of the National Academy of Sciences of the United States of America. 103: 14919-24. PMID 17003121 DOI: 10.1073/Pnas.0605390103  0.547
2006 Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nature Medicine. 12: 856-61. PMID 16799555 DOI: 10.1038/Nm1438  0.625
2006 Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. The Journal of Biological Chemistry. 281: 24566-74. PMID 16787929 DOI: 10.1074/Jbc.M602440200  0.716
2006 Brendza RP, Holtzman DM. Amyloid-beta immunotherapies in mice and men. Alzheimer Disease and Associated Disorders. 20: 118-23. PMID 16772748 DOI: 10.1097/01.Wad.0000213810.89681.A5  0.476
2006 West T, Atzeva M, Holtzman DM. Caspase-3 deficiency during development increases vulnerability to hypoxic-ischemic injury through caspase-3-independent pathways. Neurobiology of Disease. 22: 523-37. PMID 16480886 DOI: 10.1016/J.Nbd.2005.12.017  0.558
2006 Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Annals of Neurology. 59: 512-9. PMID 16372280 DOI: 10.1002/Ana.20730  0.486
2006 Brody DL, Holtzman DM. Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury. Experimental Neurology. 197: 330-40. PMID 16309676 DOI: 10.1016/J.Expneurol.2005.10.020  0.369
2006 Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holtzman DM, Morris JC. Plasma Cortisol and Progression of Dementia in DAT Subjects American Journal of Psychiatry. 163: 2164. DOI: 10.1176/Appi.Ajp.163.12.2164  0.332
2006 Bateman RJ, Munsell L, Morris JC, Yarasheski K, Holtzman DM. P2-143: Quantitation of in vivo amyloid-beta synthesis and clearance rates in humans using stable isotope labeling and mass spectrometry Alzheimer's & Dementia. 2: S275-S275. DOI: 10.1016/J.Jalz.2006.05.981  0.529
2006 Hu Y, Townsend RR, Hosseini A, Fagan AM, Holtzman DM. P2-141: Identification of CSF biomarkers for Alzheimer's disease using proteomic approaches Alzheimer's & Dementia. 2: S274-S275. DOI: 10.1016/J.Jalz.2006.05.979  0.393
2006 Lee J, Hu X, Crick S, Song H, Yin K, Cirrito J, Bateman R, Hsu CY, Xu J, Hsu FF, Turk J, Pappu R, Holtzman DM, Yan P. O4-06-07: MMP-9 degrades fibrilllar abeta in vitro and compact plaques In situ Alzheimer's & Dementia. 2: S89-S89. DOI: 10.1016/J.Jalz.2006.05.342  0.705
2006 Fagan AM, Mintun MA, Sacco D, Sheline Y, Shah AR, Spinner ML, Mach RH, Dence CS, Morris JC, Holtzman DM. IC-P-054: Relationship between in vivo amyloid imaging with 11 C-PIB and CSF Aβ42 Alzheimer's & Dementia. 2: S675-S676. DOI: 10.1016/J.Jalz.2006.05.2259  0.361
2006 Fagan AM, Mintun MA, Sacco D, Sheline Y, Shah AR, Spinner ML, Mach RH, Dence CS, Morris JC, Holtzman DM. O3-01-07: Relationship between in vivo amyloid imaging with 11 C-PIB and CSF Aβ42 Alzheimer's & Dementia. 2: S53-S53. DOI: 10.1016/J.Jalz.2006.05.193  0.37
2005 Morris JC, Kimberly A, Quaid K, Holtzman DM, Kantarci K, Kaye J, Reiman EM, Klunk WE, Siemers ER. Role of biomarkers in studies of presymptomatic Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 1: 145-51. PMID 19595847 DOI: 10.1016/J.Jalz.2005.09.013  0.471
2005 Fagan AM, Csernansky CA, Morris JC, Holtzman DM. The search for antecedent biomarkers of Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 8: 347-58. PMID 16556966 DOI: 10.3233/Jad-2005-8404  0.346
2005 Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 48: 913-22. PMID 16364896 DOI: 10.1016/J.Neuron.2005.10.028  0.685
2005 Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, Wu Z, Holtzman DM, Zlokovic BV. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 11495-503. PMID 16354907 DOI: 10.1523/Jneurosci.3697-05.2005  0.456
2005 Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. The Journal of Clinical Investigation. 115: 3285-90. PMID 16239972 DOI: 10.1172/Jci25247  0.721
2005 Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. The Journal of Biological Chemistry. 280: 43236-42. PMID 16207708 DOI: 10.1074/Jbc.M508780200  0.715
2005 Hu Y, Malone JP, Fagan AM, Townsend RR, Holtzman DM. Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Molecular & Cellular Proteomics : McP. 4: 2000-9. PMID 16199891 DOI: 10.1074/Mcp.M500207-Mcp200  0.358
2005 Fryer JD, Holtzman DM. The bad seed in Alzheimer's disease. Neuron. 47: 167-8. PMID 16039556 DOI: 10.1016/J.Neuron.2005.07.002  0.457
2005 Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 6213-20. PMID 15987951 DOI: 10.1523/Jneurosci.0664-05.2005  0.74
2005 Young C, Roth KA, Klocke BJ, West T, Holtzman DM, Labruyere J, Qin YQ, Dikranian K, Olney JW. Role of caspase-3 in ethanol-induced developmental neurodegeneration. Neurobiology of Disease. 20: 608-14. PMID 15927478 DOI: 10.1016/J.Nbd.2005.04.014  0.657
2005 Fryer JD, Demattos RB, McCormick LM, O'Dell MA, Spinner ML, Bales KR, Paul SM, Sullivan PM, Parsadanian M, Bu G, Holtzman DM. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. The Journal of Biological Chemistry. 280: 25754-9. PMID 15888448 DOI: 10.1074/Jbc.M502143200  0.518
2005 Morikawa M, Fryer JD, Sullivan PM, Christopher EA, Wahrle SE, DeMattos RB, O'Dell MA, Fagan AM, Lashuel HA, Walz T, Asai K, Holtzman DM. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta. Neurobiology of Disease. 19: 66-76. PMID 15837562 DOI: 10.1016/J.Nbd.2004.11.005  0.421
2005 Loren DJ, Seeram NP, Schulman RN, Holtzman DM. Maternal dietary supplementation with pomegranate juice is neuroprotective in an animal model of neonatal hypoxic-ischemic brain injury. Pediatric Research. 57: 858-64. PMID 15774834 DOI: 10.1203/01.Pdr.0000157722.07810.15  0.322
2005 Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 2803-10. PMID 15772340 DOI: 10.1523/Jneurosci.5170-04.2005  0.532
2005 Lee JM, Yin K, Hsin I, Chen S, Fryer JD, Holtzman DM, Hsu CY, Xu J. Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage. Journal of the Neurological Sciences. 229: 249-54. PMID 15760647 DOI: 10.1016/J.Jns.2004.11.041  0.355
2005 Maas JW, Indacochea RA, Muglia LM, Tran TT, Vogt SK, West T, Benz A, Shute AA, Holtzman DM, Mennerick S, Olney JW, Muglia LJ. Calcium-stimulated adenylyl cyclases modulate ethanol-induced neurodegeneration in the neonatal brain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 2376-85. PMID 15745964 DOI: 10.1523/Jneurosci.4940-04.2005  0.669
Show low-probability matches.